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ExEcutivE summary
This report has been commissioned from the National Treatment 
Agency for Substance Misuse (NTA) by the Department of Health 
and covers England only. The NTA has no remit over clinical 
prescribing decisions by GPs or the regulation of pharmaceutical 
products. However, its oversight of national drug treatment 
provision and access to commissioners, practitioners and 
providers of addiction and recovery services make it well placed 
to investigate the potential extent of misuse of both prescription-
only-medicines (POM) and over-the-counter medicines (OTC), and 
the current availability of services to help people addicted to them.
There were three main aspects of this work:
1. An analysis of relevant National Drug Treatment Monitoring 
System (NDTMS) data and prescription data to investigate 
prevalence and trends
2. Structured interviews with targeted PCTs/partnerships1 to better 
understand the commissioning, governance (of prescribing and 
drug treatment provision) and provision of drug treatment services 
3. Surveys and structured interviews with specialist drug treatment 
providers and dedicated providers of treatment for POM/OTC 
medicines dependency to determine what is being provided and 
how local services are configured.
This report considers the problems encountered by the use 
of psychotropic2 and opioid analgesic3 medication (such as 
diazepam and tramadol) in the general population, (including that 
encountered by people reporting problems with illegal drugs) and 
the role of health services, including specialist addiction, pain and 
primary care services in order to address these issues.
The report includes contribution from over 100 professionals 
from across England, including: service commissioners and 
medicine management leads from 88 local areas, lead clinicians, 
pharmacists, general practitioners (GPs) and specialist and 
dedicated service providers.
Despite detailed analysis of the treatment and prescription data 
available at a national level, and extensive consultation with the 
field, it has not been possible to establish a definite prevalence 
of POM/OTC medicines addiction or dependency in the general 
population. However this report does find that a level of need 
in relation to the problematic use of POM/OTC medicines is 
recognised by local areas and that people who access treatment 
services find the support they need to achieve recovery.
POM/OTC can bring comfort to many people suffering from a 
wide range of ailments and the overall use of prescription drugs is 
increasing nationally. However, it is clear some people can develop 
problems with the use of certain medicines and so this report set 
out to review the level and trends in prescribing of those categories 
of drugs that have the potential for dependency and abuse. 
The report highlights a year on year increase in the community 
prescribing of opioid analgesics from 228.3 million items in 1991 
to 1,384.6 million items in 2009, and reports an overall decrease 
in the prescribing amounts of hypnotic and anxiolytic medicines4  
from 878.7 million items in 1991 to 550.4 million items in 20095.  
Within the overall decrease of hypnotic and anxiolytic medicine an 
increase in the prescribing of z-drugs6 can be evidenced against a 
general decrease in the amount of benzodiazepines7 prescribed.  
There are large geographical differences in the amounts of these 
drugs prescribed at both Strategic Health Authority and local level. 
Previous studies have reported that higher levels of prescribing 
may be a reflection of the level of deprivation within a partnership 
area and could potentially reflect issues of poor prescribing 
practice. Treatment data indicates that there is a correlation 
between areas of high prescribing and the numbers accessing 
treatment in relation to prescribed medicines. 
Treatment for substance use disorders in England is readily available 
and quickly accessible, which means that treatment data can 
provide a useful indicator for trends in drug use. While historically, 
problems in relation to POM/OTC medicines have not been a major 
focus of drug treatment policy, the data does suggest that the use 
of these medicines are reported as problematic by a significant 
proportion of the drug treatment population.
In 2009-10, just 2% (3,735) of those in drug treatment services 
reported their primary problem was with POM/OTC (referred 
to as ‘POM/OTC-only’). A further 14% (28,775) whose primary 
dependency was illegal drugs reported additional problems with 
POM/OTC (referred to as ‘POM/OTC+’). This means that overall 
16% (32,510) of people in drug treatment services reported 
problems with their use of POM/OTC medicine out of a treatment 
population of 206,889. Despite some variation in the overall 
proportion of people entering treatment in relation to POM/
OTC between local areas, treatment data indicates that there are 
people accessing treatment in relation to POM/OTC in almost 
every local area. Importantly the national drug treatment data 
evidences that those who develop problems in relation to POM/
OTC medicines, without problematic illegal drug use, do not 
suffer long waits and can access local treatment services that 
support them to achieve recovery.
National treatment data indicates that the number of people 
coming into treatment reporting problems with benzodiazepines, 
without concurrent illegal drug problems, has fallen over the past 
five years. This might reflect information from national prescribing 
data that these medicines are being prescribed in reduced 
amounts. This possibility is further supported by local partnerships 
who have reported an increased vigilance in the prescribing of 
these medicines. However, while national treatment data does 
indicate slight year on year increases in the number of individuals 
in treatment who report the problem use of prescription only and 
over the counter opioids, the rapid increase in the prescribing 
of opioids does not seem to be fully reflected by the increase in 
treatment demand.
Eighty per cent of local partnerships that responded positively to 
the NTA’s survey (68/85) reported having local systems in place 
1 The local strategy partnership responsible for delivering the drug strategy at a local level (often known as the Drug and Alcohol Action Teams or DAAT)
2 A drug that acts primarily on the central nervous system where it affects brain function, resulting in changes in mood, perception, consciousness, cognition and behaviour
3 Opioids are drugs that are generally prescribed to manage pain
4 Drugs that can help people with sleep disorders and anxiety
5 Note: this does not take into account any potential changes to the dose strength of the compounds prescribed
6 A class of drugs that have sedative, sleep-inducing, anti-anxiety, anticonvulsant, muscle relaxant and amnesic action
7 A group of non benzodiazepine drugs with effects similar to benzodiazepines which are used in the treatment of insomnia
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with which to implement preventative activity, such as identifying 
individual practices or patients for targeted support. Treatment 
services were reported to be commissioned in line with local need. 
However, it was recognised that need in relation to POM and 
particularly, OTC medicines, can be difficult to quantify, more so 
when it exists in the absence of other substance misuse. 
Some partnerships use detailed auditing procedures to target 
improvement in prescribing practice and to identify clients in need 
of support. Other areas reported using local information networks 
including information from pharmacists, GPs, treatment services 
and local police to identify the potential prevalence of POM/OTC 
medicines problems as part of their strategic needs assessment. 
Most partnerships reported commissioning provision as part of 
specialist treatment services or from dedicated POM/OTC services 
(those services providing treatment specifically in relation to 
problem POM/OTC medicines use). 
The information collected from specialist and dedicated service 
providers supports the assertion from local partnerships that in 
terms of approach, treatment services were commissioned to 
meet individual need. Both specialist and dedicated providers 
reported treating both POM/OTC-only and POM/OTC+ illegal drug 
clients (albeit in different proportions) and indicated a flexible 
approach to treatment, based on the clients need. While it was 
felt that POM/OTC+ illegal drug client’s needs could be met 
adequately by specialist/dedicated  services, a preferred model 
to support POM/OTC-only clients was via supporting their GP  to 
manage these issues, with referral pathways into specialist or 
dedicated provision for more complex cases. 
Some local areas and services identified a potential increase in 
presentations for treatment in relation to POM/OTC pain relief. 
However, the relationship between dedicated and specialist 
drug treatment services and pain services was reported to be 
underdeveloped. Increasing access to psychological therapies (IAPT) 
was another area where partnerships and providers recognised 
that there could be further development to support local service 
provision to treat dependence on POM/OTC medicines. 
Despite recognising a clear need and providing services for 
individuals experiencing problems with POM/OTC medicines, 
partnerships and providers reported that it was difficult to quantify 
unmet need. Performance data from local services suggests that 
once a client is engaged with services, treatment seems to work 
well.  Individuals reporting problems with just POM/OTC engage 
with treatment for generally six months or more and a higher 
proportion of these individuals exit drug treatment services having 
completed treatment successfully than the wider drug treatment 
population. Importantly there are low waiting times for access into 
dedicated services, suggesting that where these services exist, they 
are meeting the demand.
Data on the proportion of those who leave treatment successfully 
suggests that 49.7% of those who leave treatment who reported 
problems with POM/OTC medicines alone, exit services having 
successfully completed treatment. This compares to 38.5% of the 
wider treatment population and just 29.4% of those in treatment 
who report problems in relation to both POM/OTC medicines 
and illegal drugs. While poorer outcomes for those who report 
problems in relation to POM/OTC medicines and illegal drugs 
might be expected, due to the likely increased complexity of these 
clients’ needs, the national treatment data does suggest that the 
impact of POM/OTC medicines use on the recovery of illegal drug 
misusers requires further consideration.
A number of areas reported that they provided more rapid 
detoxification and reduction regimes to clients reporting both 
problems with POM/OTC medicines and illegal drug use than 
to those that reported problems only in relation to POM/OTC 
medicines. Although many areas had good treatment outcomes 
for POM/OTC clients, some indicated that the provision of national 
best practice guidance would support the management of POM/
OTC medicines for all those who develop problems in relation to 
these medicines.
Service providers and partnerships welcomed the focus on 
POM and OTC medicines in the new Drug Strategy. However 
they raised concerns about how to meet a potential increase in 
treatment service demand within current resources. There was 
also a feeling among many respondents that the movement 
toward GP consortia commissioning on local governance 
arrangements would need to be carefully managed in order to 
ensure that this issue continues to be tackled effectively.
This report has not been able to identify the precise level of 
prevalence of addiction and dependence in relation to POM/
OTC in the general population. Prescribing data might be able to 
provide useful proxy indicators of increased prescription vigilance 
or trends in the level of use of prescribed medicines, but this tells 
us little about the potential or actual level of dependence that 
might be associated with these drugs.
 
It is clear that those in drug treatment are reporting an actual level 
of dependency, but given the historic focus of drug treatment on 
heroin and crack, the numbers in treatment reporting problems 
in relation to POM/OTC may be under representative of the 
wider population of people who experience problem with these 
medicines. Indeed, many local partnerships acknowledged that 
support and treatment for people who develop problems in 
relation to POM/OTC would be provided by GPs, many of whom 
do not report to the NDTMS. However, treatment data does 
suggest that there is access to treatment in most local areas and 
people that do enter treatment tend to do well, based on national 
performance measures. 
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a notE on tErminology
In this study, the term ‘addiction to medicine’ is used to refer to 
the problems some individuals can develop in relation to POM 
and OTC medicines that require clinical attention. These problems 
can be defined as addiction or dependency, based on individual 
clinical discretion. No disparagement or stigma is intended by the 
term, and it is acknowledged that a variety of terms are in use to 
describe the condition.
The terms ‘directed use’ and ‘non-directed use’ are used to make a 
distinction between the use of POM/OTC medicines. ‘Directed use’ 
refers to the use of POM/OTC medicines in the way they have been 
prescribed by a medical professional, such as a doctor, pharmacist 
or nurse prescriber, or when OTC medicines are purchased and 
used in accordance with the label and leaflet1. ‘Non-directed use’ 
refers to the use of POM/OTC medicines that would fall outside of 
this definition, such as use of medicines by an individual for whom 
they have not be prescribed or taking doses above prescribed 
levels, or, when OTC medicines are purchased, use that is not in 
accordance with the label and leaflet.
It is clear that some people’s problems can stem from the directed 
use of these medicines; others can develop problems through the 
non directed use of these drugs. However, within this study, the 
terms ‘prescription-only medicines’ (POM) and ‘over-the-counter’ 
(OTC) medicines refer to the legal category of medicine described, 
not the source of these medicines.
Separating prescription medicines from purchased OTC medicines 
can present significant challenges. Many OTC medicines 
can be prescribed by a doctor as well as purchased without 
prescription. Therefore, data on the route of supply as well as 
the legal status of the medicines is necessary if any conclusions 
are to be drawn about whether the legal status of a medicine 
impacts on addiction. Since, from the data collected, it is not 
possible to separate out the route of supply of OTC medicines, 
we use the classification of POM to refer to drugs that are only 
legally available by prescription and OTC drugs as those that are 
available on prescription and/or available for purchase without a 
prescription.
Wherever possible, such as within the analysis of drug treatment 
data, a distinction between POM/OTC medicine is made. 
However, it is important to note that this distinction is not based 
on the route of supply of these medicines.
Medicines included within the POM category are: analgesics 
including opioids (excluding opioids prescribed for the treatment 
of addiction), benzodiazepines: z-drugs and barbiturates. 
Medicines included within the OTC category are: over the 
counter opioids (mainly codeine containing compounds) and 
antihistamines (data suggests that these are less of an issue). The 
full range of substances considered is provided in Annex 1.
The primary focus of this report is on the needs of those whose 
problems are related to the prescribed or directed use of POM/
OTC. However, as access to health services should be configured 
to meet individual need, when discussing the treatment provision 
this report considers the needs of all those who develop problems 
in relation to these medicines.
Individuals who develop problems in relation to prescribed or 
over the counter medicines are likely to need to access a range 
of services whose intensity of support reflects the severity of the 
problems they experience. This might range from low intensity 
information and advice through to higher intensity treatment 
and rehabilitation services. While the provision of information 
advice and support services is considered, the main focus of this 
study is the provision of structured treatment services. These are 
services where the treatment of individuals falls within the official 
definition of structured drug treatment defined as ‘treatment 
following assessment and delivered according to a care plan, with 
clear goals, which is regularly reviewed with the client6’.
Effective provision of local treatment services for people who 
develop problems in relation to drug or alcohol use is the 
responsibility of the local strategic partnerships. These are often 
known as the drug and alcohol teams (DATs) and are referred to 
simply as, local partnerships within this report.
6 Models of Care (NationalTtreatment Agency for Substance misuse, 2006)
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introduction
The APPG held an inquiry in 2008 into addiction to prescription 
and over-the-counter medicines. Their report, published in 2009, 
recommended: more training to support doctors and other 
healthcare professionals to recognise the symptoms of physical 
dependence and addiction to all drugs; greater awareness of 
the prescribing guidelines and the potential risks associated with 
prescribed and over the counter medicines; that Primary Care Trusts 
provide appropriate treatment for those who became dependent. 
The report also recognised that not enough was known about the 
scale and implications of the problem, and recommended further 
research should be undertaken into POM/OTC.
Subsequently the DH commissioned a literature review from the 
NAC, and asked the NTA to investigate the extent of misuse of 
prescription-only-medicines and over-the-counter medicines, and 
the current availability of services to help people addicted to them.
The NTA was set up to improve the quantity and quality of 
services for those dependent on illegal drugs, and has no remit 
over GP prescribing decisions or the regulation of pharmaceutical 
products. However it runs the National Drug Treatment 
Monitoring System (NDTMS) that collects information from all 
publicly funded drug treatment services and has unparalleled 
access to the practitioners and providers of drug treatment so 
was felt by government to be the best-equipped official body to 
conduct an impartial investigation into this area of concern
This report provides an overview of the findings from the NTA’s 
work. There were three main aspects of this work that included:
1. An analysis of relevant NDTMS data and pharmacy data to  
 investigate prevalence and trends
2. Structured interviews with targeted Primary Care Trusts/Drug  
 and Alcohol Partnerships7 to better understand the   
 commissioning, governance (of prescribing and provision) and  
 the delivery of drug treatment services 
3. Surveys and structured interviews with dedicated and specialist  
 providers to determine what is being provided and how local  
 services are configured. 
The results from each of above elements have been complied 
into a single review report to provide an overview of the level and 
configuration of current service provision to support those who 
develop problems with POM/OTC.
Project scope and methodology
The focus of this report is the problems that can develop from 
the directed use of medicines for a variety of conditions unrelated 
to the treatment of substance misuse, however the use of these 
medicines alongside illegal drugs is also considered.
While information advice and support services are considered, the 
main focus of this study is the provision of structured treatment.
The scope of this project includes: consideration of psychotropic 
and opioid medicines, the problems encountered by the directed 
and non-directed use of these medicines and the role of addiction, 
pain management and primary care services in order to address 
these issues.
The problems considered are those that are assessed as requiring 
clinical attention and therefore this report does not include a 
detailed discussion of the wider advice and support that might be 
needed in relation to prescribed or over the counter medicines.
This report has been written with extensive consultation with 
the field and includes contributions from over 100 professionals 
from across the country, including; lead clinicians, service 
commissioners, medicine management leads, pharmacists, GPs 
and specialist and dedicated service providers
Unfortunately we were unable to speak to service users directly 
as part of the consultation for this report as this would have 
necessitated ethical research clearance that was beyond the scope 
of this report. (See Annex 2 for full project specification)
7 Drug and alcohol partnerships or their equivalents are high-level, strategic partnership responsible for overseeing the implementation of a strategic plan to address drug and 
alcohol use within the local area
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What national data can tEll us – national 
prEscription data
Aim
To investigate any trends and geographic variation in the level of 
prescriptions for hypnotics and anxiolytics, and opioid analgesics. 
To determine whether prescription data are useful in determining 
the likely prevalence of people who develop problems associated 
with these drugs.
Introduction
NHS Prescription Services, a division of the NHS Business Services 
Authority, collects information on all prescriptions issued by 
authorised prescribers, the majority of which are general 
practitioners that are then dispensed by community pharmacists, 
dispensing general practitioners, or dispensing appliance 
contractors (who can only dispense appliances such as stoma care 
aids, bandages, dressings etc. and not medicines). These data are 
made available to local partnerships via the prescribing toolkit 
provided by NHS Prescription Services. 
The toolkit includes several indicators for monitoring prescribing 
including a cost comparator, the net ingredient cost (NIC) which 
is the basic price of a drug, and a specific indicator for anxiolytics 
and hypnotics, the ADQ (Average Daily Quantities) per STAR-
PU (Specific Therapeutic Age-Sex Related Prescribing Unit). The 
ADQ STAR-PU provides a value that represents the average daily 
amount of benzodiazepines prescribed to an individual in a PCT, 
standardised by age, gender and diagnosis.
Using these measures a comparison can be derived of the 
level of prescribing in the different partnerships and regions of 
England. Data at a local level, primarily through e.PACT (electronic 
prescribing analyses and costs) data provide further granularity 
enabling partnerships to identify outliers at a practice level and 
target corrective action. 
The available prescribing data was reviewed in order to determine 
the level of variance at partnership level and to identify if there 
was any relationship between the level of prescribing and 
prevalence of the problem use of these drugs in local areas.
Methods
The latest available data from NHS prescription services on cost 
and ADQ STAR-PUs at sub-national and partnership level was 
reviewed and outliers identified for further investigation. Data for 
Hypnotics, anxiolytics and opiate analgesics were reviewed.
Findings 
Trends in prescribing of opioid analgesics, and hypnotics and 
anxiolytics.
Figure 1: trends in prescribing of opioid analgesics hypnotics and 
anxiolytics (by number of prescriptions (millions) and quantity in the 
number of items dispensed (1991-2009)8. (Source, DH)  
The two charts report the number of prescription items issued 
since 1991 up until 2009 and the quantity of medication 
that these prescriptions cover. As can be seen the number of 
prescriptions and the amount of opioid analgesic medications 
dispensed has increased significantly over the last 19 years, with 
both in fact having increased over five fold during this time.
The numbers of prescriptions for hypnotics and anxiolytics have 
fluctuated since 1991, however as the second chart shows 
the quantity of medication dispensed has fallen steadily which 
might suggest that these medicine types are being prescribed in 
reduced doses or for more limited durations. This does not take 
into account the possibility that prescribing may have shifted 
to higher strength compounds which would reduce the overall 
quantity. This would require further analysis of each individual 
drug categorised as a hypnotic or anxiolytic, but taken with the 
ADQ data presented below (fig.2), these trend data provide a 
good indication of reduction in the overall dispensing of this class 
of medicines over time.
Hypnotics and anxiolytics
When looking at the average daily quantity measure the level of 
prescribed benzodiazepines previous reports have indicated that 
the prescription of benzodiazepines have declined substantially 
since the release of the CSM advice in 1988 (CSM/MCA, 
1988). Analysis of the latest available data suggests that this 
decline has continued over the past five years (fig 2). However, 
benzodiazepines still account for a large number of prescription 
items, of which z-drugs are an increasing proportion. 
Figure 2: Graph showing the average daily quantities in (1000s) according to all 
8 The data covers all dispensing in primary care in England. Prescriptions written in Wales, Scotland, Northern Ireland and the Isle of Man but dispensed in England are 
included. Prescriptions written in England but dispensed outside England are not included. The data do not cover items dispensed in hospital or on private prescriptions
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Figure 2: the average daily quantities in (1000s) according to all anxiolytic 
and hypnotic prescriptions dispensed in the community in England (Jan 
2006-Dec 2010).
An examination of regional data reveals that although year on 
year decreases are achieved in the dispensing of this class of 
drugs, there is wide variation in the level of dispensing overall 
despite using a standardised measure such as the ADQ STAR-PU 
measure for benzodiazepines.
The data suggests that the lowest level of prescribing of 
benzodiazepines is within London with a value (ADQ per 1000 
STAR (09)-PU) of 1335 compared to the highest regional value of 
2177 in the North West. The North East and Yorkshire also show 
much higher relative levels of prescribing of benzodiazepines than 
the other 7 SHAs (fig.3).
Figure 3: the variation between Strategic Health Authorities in usage of 
Benzodiazepines 2008-2010 (Source, NHS prescription services).
This variation is further amplified at a Partnership level with values 
(ADQ per 1000 STAR (09)-PUs) ranging from 879 in Lewisham to 
3688 in Brighton and Hove (data available from NHS prescription 
services).
Opiate Analgesics:
Figure 4: trends in the prescribing of opiates analgesics in general practice 
in England9 (Source: DH, 2011).
Figure 5: variation between Strategic Health Authorities in prescribing of 
opioid analgesics (Quarter to March 2010) NHS prescribing services.
Tramadol is the now the most commonly prescribed opiate 
analgesic with its rise in use having increased tenfold since 1994 
when it first appears in these data (fig.4). All the other more 
regularly prescribed substances have also shown an increase except 
Dihydrocodeine which has been in decline since about 2001. 
Again there is wide variation in the levels of the prescribing of 
opiate analgesics across the different regions of the country (fig. 
5). The highest levels of dispensing are in the north of the country, 
particularly the north east.
Discussion:
Prescribing data are useful in understanding any trends in relation 
to the dispensing of medicines in terms of volume, cost and 
geographic distribution. The prescribing toolkit enables local 
partnerships to identify local outliers down to an individual 
practice level and to direct action to address this. While the data 
is helpful in determining areas with higher levels of prescribing 
and hence possibly areas where more individuals could be at 
risk of developing problems associated with these drugs, the 
data available at national level tell us little about the prevalence 
of addiction or substance dependence disorders. The current 
information systems cannot provide information regarding the 
9 The data covers all dispensing in primary care in England. Prescriptions written in Wales, Scotland, Northern Ireland and the Isle of Man but dispensed in England are 
included. Prescriptions written in England but dispensed outside England are not included. The data do not cover items dispensed in hospital or on private prescriptions
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length of prescribing and the uptake of systems to monitor the 
levels of repeat prescriptions are not yet embedded to a level that 
would permit reliable comparisons at regional or partnership level.
Current data suggest that the prescribing of opioid analgesics is 
increasing reflecting, but outpacing, the year on year increase in 
the total of all prescription items dispensed in England. The year 
on year decrease in the prescribing of hypnotics and anxiolytics 
bucks this general trend and this could be seen to be a result 
of release of CSM guidance in 1988 in relation to the use of 
benzodiazepines (CSM/MCA, 1988) and the NICE guidance 
(Excellence, 2004) regarding the use of z-drugs for the short term 
management of insomnia. The decrease in the level of prescribing 
of hypnotics and anxiolytics suggests that local PCTs are 
implementing the CSM and NICE guidance through monitoring 
audit and appropriate clinical governance systems the expectation 
of which were made explicit within the mental health national 
service framework (Department of Health, 1999) 
Despite the focus and ongoing reduction in use of hypnotics 
and anxiolytics these drugs still account for a large number 
of prescription items and a large amount of variance in the 
prescribed level of these drugs exists at a partnership level. 
Reports suggest that a great deal of variance in the level of 
prescriptions of these drugs also exists at a GP practice level (Zoi 
Tsimtsiou, 2009). While there is some support for the notion that 
high prescribing practices are less well developed (i.e. the high 
levels of prescribing are due to poor practice), the report indicates 
that demographic factors  are more powerful determinations 
of prescribing than the characteristics of the practice itself (Zoi 
Tsimtsiou, 2009). Practices based in areas with higher proportions 
of any ethnic minority, particularly black or black British people 
have been shown to prescribe fewer anxiolytics and hypnotics. 
However, Social deprivation has been shown to be the major 
determinant of prescribing volume, with more deprived areas 
reporting higher levels of prescribing. This could perhaps provide 
a partial explanation for the distribution of the prevalence of 
prescribing seen within the regional data for these drugs, with the 
highest levels of prescribing in the north of the county. This notion 
may also provide explanation for the similar pattern of prescribing 
prevalence for opioid analgesics. 
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What national data can tEll us – national 
trEatmEnt data
Aim
To use national drug and alcohol treatment data to identify any 
trends in presentation to treatment services and performance data 
to determine whether drug treatment services are meeting these 
presenting needs.
Introduction
NDTMS is a national database that collects trend and activity data 
from publicly funded substance use disorder treatment services in 
England. It collects detailed information on the treatment people 
receive, their presenting need and the outcomes of treatment. 
Analysis of these data is used to monitor drug treatment provision 
and due to the readily available access to drug treatment provision 
in England has become a useful indicator of illegal drug trends. 
One of the key data items collected by the NDTMS system is 
information on the problem substances that people present 
to treatment with. NDTMS collects data on an extensive list of 
medicines that are available on prescription or over the counter. 
While the national focus of drug treatment has historically been 
primarily on the illegal drugs evidenced to cause the most harm, 
it is down to local partnerships to configure the drug treatment 
system to best meet local need. Therefore, we would expect 
people who develop problems in relation to prescribed and over 
the counter medicines to be able to access treatment services, in 
areas where there is evidence of need. 
Benzodiazepine use is commonly a major problem among illegal 
drug users, particularly opioid users (Perera KM, 1987). Illegal 
drug users may often take POM/OTC medicines for quite different 
reasons than the rest of the population, for example, to enhance 
the effects of illegal drugs or to manage their after effects. It is 
clear that while some people might develop problems from the 
directed use of these medicines others can develop problems that 
stem from their non-directed use. 
The focus of this report is on the treatment provision for those 
that develop problems from the directed use of medicines so 
when considering the national drug treatment data within this 
report we make a distinction between individuals who report 
illegal drug use alongside problems with prescription and over 
the counter medicines (POM/OTC+ Illegal drug use clients) and 
those that report problems with prescription and over the counter 
medicines alone (POM/OTC clients).
Using national drug treatment data this study aimed to identify: 
 • trends in use of prescription only  or over the counter medicines
 • the geographic distribution of services to meet this need 
 • and the potential uptake of drug treatment services by those  
 experiencing problems with prescription only and over the  
 counter medicines.
Further analysis using NDTMS has compared the treatment 
outcomes of those that report problems with over the counter 
or prescription only medicines to those who report problem use 
of these compounds in addition to illegal drugs and that of the 
wider illegal drug using population. 
Methods
The following compounds were identified as being available as 
over the counter or prescription only within NDTMS coding and 
placed into the following classification (see table below and full 
classification in Annex 2):
Prescription-only medicines (POM)
Benzodiazepines and z-drugs; prescribed opiates (painkillers)
Over-the-counter medicines (OTC) 
Over-the-counter opiates (painkillers); antihistamines
Using national data for adults (18 years and above) presenting 
to drug treatment services indicating POM or OTC medicines 
as a problem across their treatment journey we identified two 
distinct cohorts for analysis based on whether or not those who 
have identified a problem with POM/OTC medicines report 
this in addition to other illegal drug use10. A full list of the drug 
categories is provided within the NDTMS core dataset available 
from www.NDTMS.net. 
Trend analysis
Using national data for new clients presenting to drug treatment 
services between 2005-06 and 2009-10, the individual count that 
POM/OTC compounds were indicated within a patient journey 
for each full year of data were analysed. This was to provide an 
indication of whether there are any identifiable trends in the 
different compounds reported as being problematic. An individual 
can report up to three substances as a problem through NDMTS 
and hence the total of counts within each category of POM/OTC 
are likely to represent a slight over count of the total number of 
individuals in drug treatment who report these compounds as 
being problematic, which was 9,899 people during 2009-10.
Data from those that report problems in relation to POM/OTC 
medicine use was broken down into two cohorts, those that also 
reported problematic use of illegal drugs and those that did not.
Referral source
Using national data for new clients presenting to drug treatment 
services between 2005-06 and 2009-10, the referral source for 
all those reporting to drug treatment with POM/OTC medicines 
but not reporting illegal drug use was analysed to determine any 
trends in referral for this client group. Then using national data 
for adults presenting to drug treatment services from 2009-10 the 
relative proportion of the different sources of referral between the 
POM/OTC-only and POM/OTC+ illegal drug cohort was compared.
Demographic analysis
Using national data for adults presenting to drug treatment 
services from 2009-10, the demographic profile each of the 
two cohorts of individuals reporting POM/OTC medicines use 
were compared by age, gender and ethnicity using grouped 
10 Note: for the purposes of this study those individuals reporting any drugs in relation to opiate substitution therapy (e.g. methadone) were also categorised within the illegal 
drug use grouping as this would most likely identify an individual as seeking treatment for a problem in relation to an illegal drug
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totals of the counts for the compounds within of the POM/
OTC classifications used in this study. Using grouped totals for 
the compounds within each classification provides a measure of 
individuals within each group.
Treatment effectiveness analysis
Using national data for adults in drug treatment services during 
2009-10, the performance of each of the identified cohorts based 
on the following national performance criteria were compared: 
effective engagement (the percentage of clients who stayed in 
treatment for more than 12 weeks, or if exiting before 12 weeks, 
were free of dependency on exit); planned exits (the percentage 
of clients who were discharged from treatment, completing 
treatment free of their drug of dependency) and the overall length 
of time in treatment, to give an indication of how well treatment 
services are meeting the needs of people who present with 
problems in relation to POM/OTC medicines. 
Geographic variation
Using national data for adults presenting to drug treatment 
services between during 2009-10 the geographic variation in 
service provision for people who develop problems in relation to 
POM/OTC was analysed. This was achieved by comparing service 
provision in each partnership area. The data were also broken 
down to service level to identify services with a higher proportion 
of these clients in treatment.
Findings
Twelve per cent (9,920) of the new clients reporting to drug 
treatment in 2009-10 reported problems in relation to prescription 
only or over the counter medicines. The majority of these clients 
(ten percent of the treatment population, 8,229) report these 
problems alongside problems with illegal drug use. While drug 
treatment data indicates there are far fewer reports of problem 
use of POM/OTC medicines among those who do not report to be 
having problems with illegal drug use, importantly it does indicate 
that a number of these clients who report just problems in relation 
to prescription only and over the counter medicines do have access 
to drug treatment services (1,691 new individuals in 2009-10).
Figure 6: POM/OTC compounds identified as being problematic by 
individuals new to drug treatment services who do not report problems 
with other illegal drug use (2005-06 to 2009-10).
The large majority of this group of clients report problems in 
relation to other opioids11 and benzodiazepines12. The data 
suggest a steady decrease in the numbers reporting problems 
with benzodiazepines and analgesics and a year on year increase 
of people presenting to drug treatment with problems in relation 
to z-drugs, over the counter opioids, such as codeine and drugs 
defined as prescription drugs including stronger medicines 
containing larger amounts of codeine and diamorphine (drugs 
which are commonly used for pain medication). The levels of 
prescription only opiate medicines presentations seem to have 
remained relatively stable over the five-year period (fig.6). It is 
important to note that the numbers reported against some of 
these medicines are very small so caution must be applied to the 
interpretation of this trend analysis.
Figure 7: POM/OTC compounds identified as being problematic by 
individuals new to drug treatment who report other illegal drug use 
(2005-06 to 2009-10).
The data suggested that POM/OTC medicines are a significant 
problem for illegal drug users, with benzodiazepines being cited in 
the majority of those reporting problems in relation to POM/OTC 
medicines. The data suggest that the use of POM/OTC medicines is 
a continuing issue among the illegal drug user population (fig.7).
The difference in the trends of new drug treatment entrants 
presenting with problems in relation to benzodiazepines between 
illegal drug users and non illegal drug users may reflect the 
different access that these two groups might have to the source 
of the benzodiazepines. It may be that illegal drug users source 
their benzodiazepines illicitly, whereas clients not using illegal 
drugs could be more likely to source benzodiazepines via licit 
prescriptions.  Increased vigilance on appropriate prescribing may 
have exposed fewer people to the risks associated with the long 
term use of these drugs and this could be the explanation for 
the steady decrease in the number of people presenting to drug 
treatment within this category as reported by NDTMS data. 
While these trend data provide useful information on changing 
patterns of use, some of the trends highlighted could be an 
artefact of improved reporting of a particular compound or the 
introduction of new NDTMS drug coding. Therefore some caution 
needs to be applied to the interpretation of any trends.
11 Majority reported as “other opiates” (~40%) or dihydrocodiene (~20%) 
12 Majority unspecified (~60%) and Diazepam (~25%)
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Referral source
Information from national drug treatment data suggests that 
the majority of individuals reporting problems in relation to 
prescription only and over the counter medicine either self refer to 
drug treatment services or are referred by their GP (fig.8). 
Figure 8: the percentage of referrals by source of POM/OTC-only clients 
into specialist drug treatment services between 2005-06 and 2009-10. 
(Source, NDTMS)
Figure 9: comparing the percentage of referrals by source between POM/
OTC-only patients and those in treatment who report concurrent illegal 
drug use (Source, NDTMS Data 2009-10.)
Comparing data on referral sources between the POM/OTC-only 
group and the POM/OTC+ illegal drug cohorts, indicates, perhaps 
not surprisingly, that criminal justice services play a much bigger 
role in referring clients with both problems in relation to POM/
OTC medicines and illegal drugs into drug treatment services then 
they do with the non illegal drug using cohort (fig.9). The other 
large variation is that those in the POM/OTC-only group are four 
times more likely to be referred from a GP than those who also 
report problems with illegal drug use. 
Demographics
Figure 10: comparing the proportion and demographics of individuals in 
drug treatment who report problems with POM/OTC compared to total 
drug treatment population based on new treatment journeys 2009-10.
Based on the latest available data 12.5% (9,899) of individuals 
that presented to drug treatment in 2009-10 reported problems 
in relation to POM/OTC medicines, but just 2.1% (1,684)of 
individuals that presented to drug treatment in 2009-10 report 
problems in relation to POM/OTC medicines but who do not 
report problems with illegal drug use (fig.10). The vast majority of 
people who report problems in relation to POM/OTC medicines 
are white and while those that present with additional illegal 
drug problems tend to be very similar to general drug treatment 
population in terms of age and gender, those with no illegal drug 
reported are almost twice as likely to be female and over 40.
Treatment effectiveness analysis 
Figure 11: performance data for the different cohorts of individuals 
reporting problems with POM/OTC within drug treatment services in 
2009-10. Data is provided for individuals reporting POM/OTC alone 
and individuals reporting POM/OTC and illegal drug use. The overall 
performance data for individuals in drug treatment not citing POM/OTC is 
also provided for comparison (Source, NDTMS)
The performance data for all POM/OTC cohorts suggested these 
clients stay in drug treatment for a significant period of time, 
engage well in treatment services and achieve reasonable success 
(fig.11). A slight decrease in effective engagement and successful 
completion of treatment is noted as the likely complexity of cases 
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increases from POM/OTC-only, to POM/OTC+ illegal drugs is 
also reported. However the overall level of performance of drug 
treatment services in respect of the needs of the POM/OTC-only 
cohort defined here exceeds that of the wider drug treatment 
population suggesting that, despite the fact that treatment of 
OTC/POM problems is not the primary focus of many of these 
agencies, the local treatment provided is commonly meeting the 
individual needs of this cohort.
Geographic distribution:
Looking now at all individuals in drug treatment during 2009-10 
and not just those newly presenting to drug services this shows 
32,510 clients (16% of the overall drug treatment population), 
have reported that they have problems in relation to POM/OTC, 
3,735 of whom (2% of the overall drug treatment population) 
are those that report problems with POM/OTC medicines without 
reporting problems with any illicit substances. 
At a sub-national level there is quite a large amount of variation, 
which can be seen in the table (fig.12) where in the East Midlands 
11% of clients are in drug treatment with POM/OTC medicines 
reported, compared to the North East where this proportion is two 
and a half times that at 27%. Within those that only present with 
POM/OTC medicines and no other reported illegal drug problems 
again the North East has the highest proportion at 3%.
This increased drug treatment demand in the North East could be 
in part driven by the relatively high levels of prescribing of these 
substances that can be seen in data in the previous section where 
the North East can clearly be seen as an outlier when compared to 
the other areas in England. 
Figure 12: the proportion of clients presenting to drug treatment who 
cite POM/OTC medicines in the different regions of England. (NDTMS, 
2009-10).
National drug treatment data suggests that most local areas 
are providing treatment to individuals who report problems in 
relation to POM/OTC medicines. Data from 2009-10 suggests 
that 147 out of the 149 partnerships provided treatment to at 
least ten individuals reporting problems with POM/OTC medicines 
in addition to other illegal drug use and that 120 of the 149 
partnerships provided treatment to at least ten individuals who 
reported problems with the sole use of POM/OTC medicines. The 
drug treatment data suggests that there is a wide range of drug 
treatment demand at local partnership level. Taking the North East 
area as an example, the proportion of those in drug treatment 
reporting problems in relation to POM/OTC medicines is up to 
49% for those also reporting illegal drug use and up to 6% for 
those without illegal drug use (North Tyneside) 
Partnership level data can therefore allow us to identify localities 
with a high prevalence of clients reporting POM/OTC and this 
information was used with other local information to identify the 
target sites for further investigation.
The data from the North East are provided in the graphs 
below (fig.13 & fig.14). Partnerships were identified following 
consideration of the numbers reporting problem use of POM/
OTC medicines and what these numbers meant in terms of the 
percentage of a local partnerships drug treatment population to 
account for the different size of local drug treatment populations. 
Figure 13: the local distribution of clients reporting POM/OTC+ illegal drug 
use in drug treatment reporting problems with POM/OTC within the North 
East region (unpublished data, 2009-10)
 Figure 14: the local distribution of POM/OTC-only clients in drug 
treatment reporting problems with POM/OTC within the North East 
Region (unpublished data, 2009-10)
	  	   All	  clients	  (individuals)	   Proportion	  of	  clients	  
citing	  POM/OTC	  drugs	  
(any	  use)	  
Proportion	  of	  clients	  
citing	  POM/OTC	  drugs	  
(no	  problems	  with	  
illegal	  	  drugs)	  
National	  	   206889	   16%	   2%	  
East	  Midlands	   15750	   11%	   2%	  
Eastern	   15475	   17%	   2%	  
London	   34850	   13%	   2%	  
North	  East	   14304	   27%	   3%	  
North	  West	   38550	   16%	   2%	  
South	  East	   21390	   16%	   2%	  
South	  West	   18122	   18%	   2%	  
West	  Midlands	   22969	   12%	   1%	  
Yorkshire	  and	  Humberside	   25479	   16%	   2%	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alcohol trEatmEnt data
Introduction
Formal collection of structured alcohol treatment data was 
incorporated into NDTMS from 1 April 2008. This subset is known 
as the National Alcohol Treatment Monitoring System (NATMS) 
Data Set. As only two years’ worth data is available from NATMS 
it is not possible at this stage to reliably identify emerging trends 
in relation to the alcohol treatment population.
All clients within NATMS cite alcohol as the first of their three 
problematic substances. In 2009-10, 1,297 clients presenting 
to alcohol treatment cited POM/OTC medicines adjunctively to 
their alcohol use. As with analysis using NDTMS, the total of 
counts within each category of POM/OTC medicines are likely to 
represent a slight over count of the total number of individuals in 
treatment reporting these compounds as being problematic.
Findings
1,297 (2%) people newly presenting to alcohol treatment in 
2009-10 cited POM/OTC medicines alongside their problem with 
alcohol, a significantly lower proportion than can be seen in the 
analysis of NDTMS data. A little over half of these (702) did not 
cite any other illegal drug use alongside their use of alcohol and 
POM/OTC medicines. A large majority of POM/OTC clients in 
alcohol treatment cited adjunctive benzodiazepine use, particularly 
in the group where illegal drug use was also cited (fig.15). These 
findings should be interpreted with caution because the overall 
numbers involved are very small.
Figure 15: count of POM/OTC compounds being adjunctively cited by 
clients presenting to alcohol treatment in 2009-10  
(Source, NATMS 2009-10)
Referral source
The majority of individuals reporting problem in relation to 
POM/OTC medicines only alongside their alcohol use self-refer 
to services (39%) or are referred by their GP (18%). These 
proportions are similar to the overall alcohol treatment population 
(37% and 21% respectively). However, larger proportions of 
those who cited POM/OTC medicines use alongside other illegal 
substances and alcohol were referred from another drug (or 
alcohol) service or through the criminal justice system (fig.16).
Figure 16: the percentage of referrals by source between POM/OTC-only 
patients reporting other illegal drug use (top) and those that do not.
Demographics:
Figure 17: the proportion and demographics of individuals in alcohol 
treatment services who report problems with POM/OTC medicines 
compared to the total treatment population (Source, NATMS 2009-10).
Clients presenting to alcohol treatment who cited POM/OTC 
medicines use without additional illegal drug use show a similar 
demographic breakdown to the general presenting population 
in NATMS, considering the relatively small size of this group. 
However, a slightly higher proportion of these clients were female 
(fig.17). Clients who cited POM/OTC medicines use, alcohol use 
	  
No illegal drug use Illegal drug use
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and illegal drug use show a different make-up to the overall 
population as proportionally fewer clients are over 40 and more 
are male, however this may be reflective of the population who 
cite illegal drugs adjunctively to alcohol use (as many clients in 
NATMS will not cite any illegal use). Additionally, the POM/OTC 
medicines cohorts show a similar gender breakdown to their 
equivalent cohorts in NDTMS data.
Geographic variation
Figure 18: the proportion of clients presenting to alcohol treatment who 
cite POM/OTC medicines in the different regions of England. (Source, 
NATMS 2009-10).
As discussed above, the proportion of clients presenting to alcohol 
treatment who cite POM/OTC medicines is small (2%). As with the 
data from NDTMS, the East Midlands have the smallest proportion 
of POM/OTC clients (at 0.7%) and the North East has the highest 
proportion at (2.9%). A larger proportion of clients presenting to 
alcohol treatment in the North East cite both POM/OTC medicines 
use and illegal drug use alongside their alcohol use (fig.18).
Discussion
National drug and alcohol treatment data indicate that people are 
presenting to drug and alcohol treatment services with problems 
related to prescription only and over the counter medicines. 
Data from alcohol services suggests that just 2% (1,297) people 
newly presenting to alcohol treatment in 2009-10 cited POM/OTC 
medicines alongside their problem with alcohol. A greater wealth 
of data regarding POM/OTC medicines was found within national 
drug treatment data and hence the following discussion focuses 
on analysis of provision reported by drug treatment services.
Twelve-and-a-half per cent (9,899) of people newly presenting to 
drug treatment during 2009-10 reported their use of prescription 
only and over the counter medicines as being a problem. As one 
might expect, the majority of these clients also have problems in 
relation to other illegal drug use. However, there were a number 
of clients (1684), just 2.1% of the national drug treatment 
population, who reported problems with prescription only and 
over the counter medicines without reference to illegal drug use.
Trend data indicate that while the majority of individuals reporting 
problems in relation to prescription only  and over the counter 
encounter problems with benzodiazepines and prescribed 
opiates, increasing numbers of individuals are presenting to drug 
treatment in relation to z-drugs, other prescription only drugs 
and over the counter medicines. The slight but increasing trend in 
presentations with problems in relation to z-drugs might reflect 
an increase in their use since their introduction as an alternative to 
benzodiazepines for insomnia and other sleep related disorders.
Issues in relation to benzodiazepine predominate within the POM/
OTC+ illegal drug cohort, likely reflecting a level of non-directed 
use of these drugs within this cohort, reported elsewhere (Perera 
KM, 1987). Treatment data highlight increased reporting of 
problems with these drugs year on year up until 2009-10 and 
ongoing increases in the number of individuals reporting problems 
with z-drugs, barbiturates, and other POM/OTC medicines. While 
caution must be applied with the interpretation of trend data, this 
does raise an interesting question about the potential diversification 
of drug use within England’s illegal drug using population.
The readily available access to drug treatment in England means 
that treatment data can provide a useful indicator for trends in 
drug use. While problems in relation to over the counter and 
prescription only medicine have not been the main focus of 
current drug treatment systems nationally, the data does suggest 
that these medicines are increasingly being reported as a problem 
within the illegal drug using population. Importantly the data 
provides evidence that individuals without reported problems with 
other illegal substances can access local drug treatment services, 
without experiencing long waits and achieve relatively good 
outcomes, based on national performance data. 
Further analysis of these data has enabled us to determine that 
these clients have a different demographic to our usual clients 
and that once in treatment they engage better with services than 
the wider treatment population (based on national performance 
indicators). This suggests that despite a likely increased level of 
complexity particularly with clients who report problems in relation 
to POM/OTC medicines, local drug treatment meets their individual 
needs. The significant period of time that most POM/OTC clients 
are engaged with drug treatment (ten months plus) could be seen 
to be supportive of the suggestion that treatment is being provided 
over a timeframe that is appropriate for this client group and might 
reflect that reduction and withdrawal from benzodiazepines are in 
line with British National Formulary (BNF) guidance.
The data on all individuals in treatment and not just those newly 
presenting to drug services indicates that there were a total of 
32,510 individuals in treatment reporting the problem use of POM/
OTC medicines during 2009-10, 3,735 of whom reported this in 
the absence of problems with illegal drugs. Using the geographic 
information within the national data these numbers were broken 
down further to identify partnership areas and services where there 
were a higher proportion of these clients in drug treatment. These 
data were used alongside other local information and evidence, 
from local teams and the partnerships and services themselves, to 
identify the local partnerships and services that were the focus of 
the further investigative work reported later in this report.
Region	   All	  clients	  (individuals)	   Proportion	  of	  clients	  
citing	  POM/OTC	  drugs	  
Proportion	  of	  clients	  
citing	  POM/OTC	  
drugs	  and	  illegal	  drug	  
use	  
East	  Midlands	   4793	   0.7%	   0.3%	  
Eastern	   7027	   2.3%	   0.8%	  
London	   10743	   2.2%	   1.1%	  
North	  East	   5426	   2.9%	   1.5%	  
North	  West	   14536	   1.6%	   0.6%	  
South	  East	   8669	   2.2%	   0.9%	  
South	  West	   6074	   1.9%	   1.0%	  
West	  Midlands	   7804	   1.2%	   0.7%	  
Yorkshire	  and	  Humberside	   7448	   0.9%	   0.6%	  
National	   72641	   1.6%	   0.8%	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an ovErviEW of thE local rEsponsE to problEm 
pom/otc mEdicinEs usE – national picturE
Aim
To develop a national overview of local understanding and 
action in relation to: the prevalence of problems in relation to 
prescription only and over the counter medicines: the preventative 
measures in place and the local services provided.
Introduction
National data can provide useful information on general trends 
and likely distribution of services to meet the needs of people who 
develop problems in relation to POM/OTC. Local services should be 
commissioned and provided in a way that best meet local need. 
Therefore, the best information in relation to the likely prevalence 
of this problem and the provision of prevention and treatment 
services should reside with the local partnerships that commission 
and provide these services. These local partnerships are commonly 
called DATs (drug and alcohol action teams) and sit within the 
Local Authority or Primary Care Trusts (PCTs). Irrespective of where 
these partnerships sit, there is an expectation that there are good 
links with the PCT who are ultimately responsible for the clinical 
governance of drug treatment and addiction services. This should 
include appropriate linkage with medicine management groups 
and the local officers responsible for controlled drugs.
 
To obtain a national overview of these issues, ahead of any 
targeted investigation, the following questions were reviewed 
with all local partnerships:
 • what is the local prevalence of need in relation to services for  
 people who develop problems with POM/OTC medicines?
 • what prevention measures are in place to reduce the likelihood  
 of patients developing problems in relation to POM/OTC  
 medicines?
 • what local services are available for people who develop  
 problems in relation to POM/OTC?
 • are there any local examples of best practice in relation to  
 addiction to medicines work?
Method
Those responsible for commissioning local addiction services and 
for the governance of medicine management groups in each of 
the 149 partnerships areas  across England were contacted with 
information regarding this study and asked to submit information 
in relation to the key questions detailed above. This was followed 
up by contact and discussion with representatives from the 
regional NTA teams. Information was submitted by email from 87 
of the 149 local partnerships and collated centrally
Findings
Two of the partnerships contacted felt that issues in relation 
to prescription only or over the counter medicines were not 
within the remit of the DAT and were unable to access this 
information from the PCT, whom they felt were responsible for 
the governance of these issues. However, a positive response was 
received from the majority of partnerships (85 out of 149).
The local understanding of the prevalence of need: 74% of 
those partnerships who responded positively to the questionnaire 
reported that they had a level of understanding regarding the 
local prevalence of need for services in relation to POM/OTC 
medicines. 
The majority of these partnerships based their understanding 
on data from local drug treatment services and their findings 
supported those from national treatment data. Partnerships 
reported that this was a significant issue for people with 
concurrent illegal drug problems, but less was known about those 
who were only experiencing problems with prescription only or 
over the counter medicines or those who do not present to drug 
treatment.  
Some partnerships reported access to a wider range of data 
including that from support services that do not report to NDTMS 
and in some cases, information from criminal justice agencies, 
such as information on controlled drug seizures and burglaries 
from pharmacies. These areas identified the internet as a 
significant source of POM/OTC medicines and suggested that this 
was a growing local issue for treatment providers and criminal 
justice services.
A handful of partnerships also identified OTC only as a growing 
potential issue and were monitoring this with information from 
pharmacies via their controlled drug local intelligence networks. 
Prevention initiatives: 80% of those partnerships who 
responded positively to the questionnaire reported that there 
were local prevention initiatives in place to address issues in 
relation to POM/OTC medicines.
The majority of partnerships indicated that preventative initiatives 
were led by the local medicines management groups based within 
the PCT. The levels of prescribing across different health services 
were reported to be reviewed at a local level and this information 
was then used to target corrective action where necessary. 
Partnerships also reported the provision of training and awareness 
for GPs and pharmacists about the potential dependency issues 
associated with POM/OTC and the support services available. 
Although most partnerships reported awareness of the relevant 
BNF guidance to audit and improve practice, some were unsure 
about how this was implemented locally; suggesting that these 
areas need to improve the relationship between the DAT and the 
medicine management groups.
Local service provision: 94% of those partnerships who 
responded positively to the questionnaire reported that there was 
local service provision in place for those that reported problems in 
relation to POM/OTC medicines.
Local partnerships stated that people who were engaged 
with drug treatment with concurrent problems in relation to 
illegal drugs would have direct access to treatment provision 
and support from within the specialist drug treatment service. 
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However, the first port of call for individuals with problems 
with POM/OTC medicines only was commonly perceived to be 
best placed within conventional primary care settings. Local 
partnerships reported that GPs were supported by specialist 
addiction and prescribing services and that wherever possible, 
issues in relation to POM/OTC medicines were managed by GPs.  
Many partnerships reported that they had in place care pathways 
into specialist services for more complex cases, although some 
reported more work was needed to formalise these pathways 
within future service level agreements and that national best 
practice guidance was needed to support this.
One commissioner confirmed the widely held view that POM/
OTC clients are best treated within primary care, under shared 
care arrangements. They noted that the Royal College of General 
Practitioners (RCGP) have been running training on POM/OTC 
for a number of years and felt that further best practice guidance 
from RCGP on tackling this issue would be useful.
In addition to this model of supported primary care provision, 
some partnerships reported commissioning dedicated service 
provision to meet the specific needs of those who developed 
problems in relation to POM/OTC medicines. These services 
were reported to be commissioned from both the statutory and 
voluntary/third sector.
Best practice: 54% of those partnerships who responded 
positively to the questionnaire nominated an aspect of their 
approach to POM/OTC medicines as best practice. This indicates 
that the issue of addiction to medicines is currently held with a 
reasonable level of priority and may be indicative of partnerships’ 
confidence in dealing with this issue.
 A range of practice initiatives were described, the majority 
focused on the implementation of the appropriate review of 
prescribed drugs and the corrective action taken to address this 
within local practices. For example, one NHS trust reported a 
reduction in prescribing levels of benzodiazepines/ z-drugs by up 
to 50% over a two-year period following the implementation of a 
local protocol to identify and target service improvements.
Other areas identified dedicated service provision as providing 
best practice and the development of specialist nurse posts and 
pain clinics with strong links to addiction services. 
Another area highlighted the consultation work they had 
undertaken with service users to raise awareness about the risks 
associated with benzodiazepines and to better identify patterns of 
use and prevalence across the local area.
Discussion
The information provided by local partnerships suggests that the 
majority are aware of current BNF guidance in relation to POM/
OTC medicines and have local systems in place with which to 
implement preventative activity. However, not all partnerships 
responded to the request to submit information in relation to 
this review and two partnerships stated that responding to 
these issues was not within their local remit. This would suggest 
that the local response in relation to POM/OTC medicines is not 
uniform across the country and may require further focus in some 
local areas.
Given the availability and utility of NDTMS data it is 
understandable that most local partnerships base their knowledge 
of the prevalence of problems in relation to POM/OTC medicines 
on those in drug treatment. Information from local partnerships 
reflects that from national drug treatment data suggesting that the 
majority of those currently in drug treatment for problems relating 
to POM/OTC medicines have concurrent issues with illegal drug 
use. While a significant number of individuals with problems with 
POM/OTC medicines only drug users do access drug treatment 
services, local Partnerships reported difficultly in quantifying the 
level of need within this population. This is perhaps not surprising 
as the service provision for this cohort was reported to be delivered 
by local GPs, many of whom would not report to NDTMS for 
activity relating to the treatment of OTC/POM addiction.  
Some partnerships reported information from seizures and 
controlled drug information networks and suggested that the 
internet was becoming a major source for prescription and over 
the counter medicines. A few local areas also provided anecdotal 
evidence of a rise in problems in relation to OTC medicines that 
reflects the trends reported by the national drug treatment data.  
It is clear that many areas have developed good relationships 
between primary care and specialist addiction services that 
support GPs to manage issues in relation to prescription only 
and over the counter medicines within primary care. Importantly 
this model of provision includes referral pathways into specialist 
or dedicated provision for more complex cases. Although many 
areas report good treatment outcomes for this client group some 
indicate that the provision of national best practice guidance 
would support the management of POM/OTC medicines for all 
those who develop problems in relation to these medicines.
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a rEviEW of local practicE – partnErship sitE 
visits
Aim
To develop a detailed understanding of local practice and 
governance, and the prevalence of problems in relation to 
prescription only and over the counter medicines, as well as the 
preventative measures in place and the local services provided. 
Introduction
Information from the partnerships survey provided a good 
national overview of the level of understanding and provision 
developed by local partnerships in relation to prescription 
only and over the counter medicines. In order to develop this 
understanding further, site visits were organised to ten of the 
local areas. Responsibility for ensuring the provision of treatment 
services appropriate to local need lies within the local strategic 
partnerships for drugs and alcohol often led by the  drug and 
alcohol commissioner and governance for prescribing lies within 
the PCT – often with a lead prescriber. Therefore engagement 
from both these bodies was sought as part of the local visits.
Method
Following the completion of the partnership survey, ten local areas 
were selected for follow up site visits and asked to participate 
in a detailed structured discussion regarding their local strategic 
response into the question of prescription only and over the 
counter medicines. These partnerships were chosen to ensure 
good geographic representation and selected on a range of 
criteria including:
 • the existence of dedicated POM/OTC medicines services
 • a high prevalence of POM/OTC clients within their drug 
treatment population, and/ or 
 • a higher prevalence of local prescribing of these medicines.
Local participants in the discussion included:
 • the drug and alcohol commissioner
 • pharmacy leads 
 • medicine managements lead
 • local provider representatives. 
All the discussions followed a common format that included the 
following theme areas:
 • audit processes
 • preventative measures
 • understanding the local problem
 • service provision, and
 • service performance.
Findings
Audit processes: in order to gain an understanding of what 
has been learnt from any recent audit process in relation to 
prescription only medicines and to identify any best practice or 
barriers to ensuring appropriate governance, partnerships were 
asked a series of questions around auditing processes.
Of the ten partnership areas that took part in the study eight 
had undertaken an auditing process in relation to hypnotics and 
anxiolytics or analgesics, most of which were conducted within 
the last 12 months. One of the partnerships responded that 
although they had not undertaken a full formal audit within the 
last 12 months, prescribing of these drugs fell under quarterly 
governance reviews, as part of medicines management processes.
The audits focused on a range of issues including: the number of 
people on high doses of prescribed medication; the level of and 
length of dosing; patterns of use and any contact patients had 
with mental health and substance misuse services.
The audits were used to identify need, trends and gaps in 
provision to ensure that patients received appropriate advice, 
information and care in relation to the prescription of these 
medicines. While two of the partnerships reported that they were 
still waiting on the outcome of their most recent audit, other 
partnerships reported using the information from their audit to 
identify local surgeries and patients for targeted support to reduce 
the levels of their prescriptions
Audits also gave partnerships a new level of intelligence about the 
patients in need of support, supplying them with demographic 
information on this client group as well as showing gaps and 
trends in this area. Partnerships reported using these data to 
inform commissioning decisions. For one partnership their audit 
justified the creation of a new post specifically concerned with 
those who had developed problems. Other partnerships stated 
that the auditing process helped raise the profile of issues in 
relation to the prescribing of these medicines and highlighted the 
need for improved information sharing and prescribing practices 
within some services. 
In terms of best practice and what might be useful for others, 
one partnership suggested that the development of GP software 
interface auditing tools was key, as this provided a mechanism for 
ongoing auditing and review. Another partnership reported that 
a multi-service agreement to standard prescribing protocols was 
important to ensure consistency in prescribing policy and practice 
across all services.
Despite the clear benefits gained, some of the partnerships 
highlighted barriers and difficulties involved in undertaking an 
audit. Some areas stated that the process was overly burdensome 
and that it took staff away from delivering front line services. 
Others stated difficulties with getting agreement from some GPs 
to be involved in the process. 
One area raised an interesting issue in relation to the auditing 
process by identifying that patients might be able to escalate 
their dose above the prescribed level by picking up their repeat 
prescriptions early. They stated that unless partnerships identified 
the received dose rather than just the prescribed dose, patients 
who might be in need of extra support or at risk of developing 
problems in relation to their prescription could be missed. 
19
NTA 2011
Preventative measures: to gain an understanding of the 
preventative measures implemented at local level, partnerships 
were asked what was in place to reduce the likelihood of people 
developing problems in relation to prescription only and over the 
counter medicines.
All of the partnerships that took part in this study reported a 
range of preventative work in this area. In addition to the auditing 
work described above, prevention work included: providing  
communications and publicity warning people about the risks of 
addiction and dependence (such as that provided by the British 
Pain Society (The British Pain Society (publications), 2010) training 
staff and  as reported in one local area, a web based information 
and training resource for GPs. 
Some of the partnerships stated that community pharmacies in 
their area were aware of the common medicines of misuse, such 
as codeine preparations and as a result they treat these medicines 
with more caution and, where appropriate, have limits on how 
much can be purchased by one person. Other partnerships 
produced a local network bulletin that raised the issues in relation 
to benzodiazepines with local GP practices and also ran GP and 
pharmacy training sessions twice a year. Attendance at such events 
was written into local PCT contracts with GPs and pharmacists to 
ensure all local services had staff that were trained to recognise 
and take action when someone might be at risk of developing 
problems in relation to prescription or over the counter medicines. 
Partnerships reported having strict guidelines and processes in 
place to address potential leakage from diverted or aberrantly 
increased prescriptions. 
All partnerships reported having governance structures in place to 
give assurance over prescribing policy and review within their area. 
For most, this responsibility sat within their medicines management 
group within the PCT. A good range of professional representation 
was reported at these groups, such as the medicines management 
lead, relevant GPs, service providers, lead pharmacists and in 
some cases even representation from prison GPs. However, some 
partnerships indicated that although these groups performed well 
operationally, the group was often not high level enough to drive 
the strategic changes that were needed in practice. 
A central problem raised by a number of partnerships was that 
there often seemed to be conflicting messages about where the 
responsibility for dealing with problems in relation to prescription 
only and over the counter medicines should sit and what should 
be done about these problems. One partnership suggested more 
preventative work could be around education, such as posters 
(displaying the potential risk of these compounds) in pharmacies 
and GP surgeries. Another added that better signposting of 
information to services that may be able to help patients with, for 
example, benzodiazepine withdrawal, would be useful.
Most areas agreed that a definitive guideline would help combat 
many of the problems associated with preventative work in this 
area, such as conflicting messages and confusion over the roles 
and responsibilities of GPs, other prescribers, mental health and 
drug treatment services.
Understanding the local problem: key to dealing with the 
problems associated with prescription only and over the counter 
medicines is understanding the local problem. Partnerships were 
asked a number of questions with regard to the work undertaken 
to develop their understanding of the local need in relation to 
POM/OTC and to discuss what evidence exists locally on the 
presenting needs of this group.
While some partnerships relied solely on information from their 
local drug treatment services, others developed specific needs 
assessment process and strategy groups to improve the level of 
local understanding in relation to POM/OTC medicines.
In some partnership areas, the medicines management group 
were reported to have taken forward work to improve local 
understanding of the needs of this cohort. One partnership area 
recently set up a strategy steering group involving medicines 
management and a range of treatment professionals, with varying 
backgrounds (substance misuse, mental health, commissioning, 
GP and pharmacist) to further develop the local strategy for 
addressing problems in relation to POM/OTC medicines.
Other areas raised the importance of consulting with service users 
to better understand how problems develop and what type of 
support should be provided. One partnership reported including 
police as full members of the medicines management governance 
meetings in order to discuss issues of burglaries from pharmacies 
and illegal supply. Another partnership reported running focus 
groups with POM/OTC clients in order to obtain intelligence on 
everything from the demographics of this client group to how 
they obtain these drugs.
Most partnerships were less confident about their knowledge 
in relation to people who develop problems in relation to OTC 
medication. One partnership noted that often in the wider 
population (outside of the drug treatment population) data on 
this client group just did not exist. 
In terms of trends in presenting need in relation to the 
problematic use of POM/OTC medicines, most partnerships 
reported that they did not perceive much of a change over time 
in treatment demand for prescription medicines. Benzodiazepines 
were reported historically and currently to be the most common 
drug that people developed problems with. However, some 
partnerships stated that they were beginning to see a small 
number of people presenting to services in relation to over the 
counter codeine based medicines.
Service provision: in order to gain an understanding of what 
local service provision is in place and how services are configured 
and commissioned, partnerships were asked a series of questions 
on the services provided in their area.
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In most partnership areas, a full range of services were 
commissioned, based on local need. Individuals reporting 
problems with POM/OTC medicines were reported to have 
access to all services assessed as being appropriate to their need. 
Treatment interventions mainly focused on talking therapies and 
counselling support provided by specialist or dedicated services 
or as part of supported GP services. More intensive treatment 
interventions, such as inpatient detoxification and residential 
rehabilitation were less likely to be delivered from specialist 
or dedicated services targeting POM/OTC clients, but referral 
pathways were reported to be in place for these more intensive 
interventions when required. Most partnerships commissioned a 
range of statutory, voluntary and private sector services. 
Referrals into drug treatment services were reported to come from 
a variety of sources: self; GP; friends and family; health and social 
care services; mental health services and pain services. The most 
popular point of referral for individuals reporting problems solely 
in relation to POM/OTC medicines was self referral, followed 
closely by GP referrals.
Most partnerships indicated that a good level of multi-agency 
support was available and that specialist and dedicated treatment 
services worked with a range of other services such as GP 
services, mental health, other drug treatment services and health 
and social care services. However, the level and formality of these 
local agreements varied from across the different partnerships 
areas. In some areas, joint working was based on the knowledge 
and commitment of individual staff; others had agreed referral 
protocols and some partnerships reported embedding a close 
joint working and care management of this client group via an 
integrated service approach.
Only a few of the partnerships interviewed reported having 
formalised pathways and joint working with acute pain services. 
Most indicated that this was an area for further development. 
In addition, all areas agreed that IAPT programmes had the 
potential to add value to local programmes in relation to POM/
OTC medicines, as an alternative to medication and as a source of 
support during reduction or stopping medication. However, there 
were some concerns that these programmes might not have the 
capacity to take on these problems.
When asked if there were any differences in the way services 
could be provided to someone with a concurrent drug or alcohol 
problem and someone who was just presenting with a problem 
in relation to prescription only or over the counter medicine, most 
partnerships stated that there would be no difference because 
the services that were offered were based on individual need. 
However partnerships did highlight that to provide services based 
on individual need often required a certain amount of flexibility 
in approach. Traditional services were not always felt to be 
appropriate environments for individuals experiencing problems 
solely in relation to POM/OTC medicines, and partnerships 
indicated that these clients were often best served by a supported 
GP model of treatment. Where they were available, dedicated 
POM/OTC medicines services were felt to be a valued aspect of 
local drug treatment systems. The therapeutic allegiance of these 
dedicated services with their service users with regard to the 
specific impact of POM/OTC medicines was reported to support, 
not just the engagement of those just with problems in relation to 
POM/OTC but, also those with problems in relation to concurrent 
illegal drug use. This suggests that dedicated services are not 
limiting their services to POM/OTC-only clients and that there may 
be some learning from dedicated services that might benefit the 
wider treatment system.
For most partnerships, there were no differences in how these 
services were commissioned for those requiring support just in 
relation to POM/OTC medicines and for those with concurrent 
illegal drug use problems. However, detoxification and reduction 
schedules were questioned, as current guidance for detoxification 
and reduction from illegal use of benzodiazepines for an 
individual with concurrent drug use indicates that this should 
last no more than six months (Substance Misuse Management 
in General Practice, 2005). Guidance in relation to reduction 
for individuals without concurrent drug or alcohol problems 
recommends a longer tapering of prescriptions.
Despite providing access to services for those reporting problems 
in relation to POM/OTC medicines, one partnership did comment 
that most drug treatment services were not initially set up to meet 
the needs of those who have developed problems in relation to 
drugs that they have been directed or prescribed to take and 
raised concerns about whether they would have the capacity to 
manage any potential increase in demand from this cohort. They 
suggested that the treatment of those developing problems in 
relation to the medicines they have been prescribed or directed 
to take, in fact, required a different management and delivery 
framework.
When asked what they felt would support the future provision of 
services to people experiencing problems in relation to POM/OTC 
medicines, partnerships indicated that there needed to be further 
clarity at a national level for the responsibility of meeting this need. 
One area stated that there was a need for a specific budget, multi-
agency working (for consistency) and governance structures to 
be in place, Another partnership stated that clarity is needed with 
regards to how prescribing governance and service provision will 
be managed under future GP consortia commissioning.
Service performance: partnerships were asked a series 
of questions regarding performance and outcomes of local 
services in order to gain an understanding of the oversight that 
commissioners have. Current capacity of services to meet this 
identified need varied from place to place.
Many partnerships made provision for the patients presenting 
with POM/OTC medicines problems as part of the commissioning 
of wider drug treatment services and stated that therefore 
there were no places specifically reserved for this cohort. Other 
partnerships had commissioned dedicated places to meet this 
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need. Demand for treatment was measured via waiting times and 
other treatment and wider partnership data.  
For most partnerships, the ultimate outcomes and objectives that 
services were commissioned to deliver in relation to people who 
develop problems in relation to prescription only and over the 
counter medicines are the same as those of illegal drug users – 
abstinence and recovery.
In terms of what could be done nationally to support the 
effectiveness of these services the majority of partnerships stated 
that more and better information in this area was required. This 
ranged from general information to best practice guidance. In 
addition to the information itself, most noted that there needed 
to be better information sharing and partnership working. One 
area in particular said that there was a need to develop GP 
software that is capable of auditing levels and trends of prescribed 
medication. 
Many partnerships stated that more work was required nationally 
to ensure areas had the correct information and authority to 
prevent these problems from starting in the first place. They 
suggested that there needed to be clearer guidance for GPs and 
pharmacists, information on other potential sources of these 
medicines (such as the internet) and greater authority for local 
areas in addressing this issue. 
One partnership agreed that appropriate assurance of prescribing 
was important but raised a concern that the focus on the 
potential problems caused by these medicines could prevent or 
dissuade GPs and other prescribers from providing medication to 
whom it can benefit. 
“We must be careful about going too far, the use of these 
medicines have a wealth of evidence supporting their benefit, 
where prescribed appropriately and we need to be careful that 
we don’t scare GPs and other prescribers away from providing 
treatments that are very effective in improving health and well 
being of our patients. We have to get the balance right.” 
Discussion
Most areas reported having an audit process in place that 
identified outliers for targeted support. Outcomes from these 
audits included a reduction in prescribing levels, improved 
partnership understanding of the issues and in some areas, 
increases in dedicated POM/OTC medicines treatment provision. 
Difficulties were identified such as the lack of appropriate 
software systems to audit effectively, the time it took to undertake 
an audit, resistance from some GPs and the need to manage 
any potential impact on governance under future GP consortia 
arrangements.
The partnerships described a range of locally developed 
preventative measures that included: Leaflets; websites; auditing 
tools; targeted GP resources; local networks/bulletins and strict 
guidelines on reissuing prescriptions. Partnerships reported that 
it was more difficult to understand and implement preventative 
measures in relation to OTC medicines than POM and illegal drugs 
and stated that more definitive and direct guidance in how to 
manage these issues were required at a national level. 
The local understanding of the issues in relation to POM/OTC 
medicines was developed formally as part of the joint annual 
needs assessment in a few partnerships. Others reported that 
they had in place a series of strategic steering groups with good 
communication with GPs, pharmacist and in consultation with 
user groups. In some cases this also included information sharing 
with the police and local intelligence networks. The local areas 
who were targeted as part of the site visits did not report that 
there were many changes in terms of trends in problematic 
benzodiazepine use other than the source of these medicines 
moving away from leakage from prescriptions toward internet 
and other illicit sources. There was some indication of an increase 
in OTC problem use although little hard evidence was available to 
support this assumption.
All partnerships reported commissioning services based on local 
need and stated that there was access into specialist treatment 
provision both for POM/OTC-only and POM/OTC+ illegal drug 
using cohorts. Referrals for the POM/OTC-only clients were in 
main reported to be self and GP and partnerships suggested that 
this provision was best located within primary care and supported 
by specialist services, unless a dedicated service was in place.
Not many partnerships had considered pathways into IAPT for this 
cohort but those who had stated that this could be difficult due 
to local IAPT services already being oversubscribed. In addition 
pathways into acute pain services seem to be under developed. 
Further development of joint working between dedicated and 
specialist drug treatment services could be important given 
the association of the use of benzodiazepines, hypnotics and 
anxiolytics in association with chronic pain diseases (Lui, 2010).
Partnerships requested clarity of the roles and responsibilities in 
relation to POM/OTC medicines, as although many areas had 
appropriate systems in place, some of these partnerships felt a 
restatement of where responsibilities lie would be required with 
the advent of GP consortia arrangements
The outcomes of service provision were reported to be focused 
on abstinence and recovery. However, some felt that performance 
monitoring of POM/OTC medicines provision (particularly that 
within dedicated services) needed improvement.
Partnerships stated that they needed better information 
(particularly in relation to potential OTC needs), better information 
sharing arrangements, improved GP software for auditing and 
better accessibility for early interventions services.
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a rEviEW of local provision – information from 
spEcialist/dEdicatEd sErvicE providErs 
Aim
To understand how treatment services are provided to clients 
reporting problems with POM/OTC medicines.
Introduction
This study aimed to obtain a better understanding of how services 
are provided to meet the needs of people who develop problems 
in relation to prescription only or over the counter medicines 
by directly targeting service providers that were known to be 
providing services in relation to POM/OTC medicines. 
Method
National drug treatment data were utilised to identify dedicated 
POM/OTC medicines services or other specialist drug treatment 
services reporting a proportionally higher level of service provision 
for this cohort of individuals. In addition, as it was recognised that 
some dedicated services might not report to NDTMS, information 
was sought from local partnership and online resources, such 
as www.benzo.org.uk. These services were asked to complete 
a survey with regard to POM/OTC provision. Of the 48 services 
approached, 24 agreed to be involved in the study and completed 
the survey. Six services were then targeted for site visits and asked 
to take part in a follow-up detailed discussion with regard to the 
local issues of POM/OTC medicines.
Survey findings
All services that agreed to be involved in the study were found to 
be reporting to NDTMS. This is perhaps not surprising given that 
one of the mechanisms for identifying services centred on NDTMS 
data. However, it is positive to note that many of those services 
identified via local partnerships and through on-line resources 
were submitting national drug treatment data. Despite all services 
reporting to NDTMS, some services indicated that there was some 
confusion about the level of information regarding POM/OTC-
only clients that should be reported.
Services included within the study represented a good range of 
statutory sector providers (50%) and voluntary sector providers 
(35%) with the remaining identifying themselves as being a 
combination of both (17%). These services were from 16 different 
local areas and therefore represented a good spread of drug 
treatment provision across the whole of England. 
Not all services were able to provide funding information, perhaps 
reflecting a level of complexity of local funding arrangements or 
difficulties in disaggregated funding for POM/OTC provision from 
the wider drug treatment system. However, for the 16 services 
that did provide funding information, the level of funding was 
reported to range from £45k to £5.15m and totalled nearly £28m 
across all 16 services. It is important to note that this funding 
information was from specialist drug services as well as dedicated 
POM/OTC medicines treatment services, so not all of this funding 
would be spent treating people with POM/OTC medicines 
problems. The majority of funding for these services was reported 
to be established from PCT and LA budgets. 
While these services were selected on the basis of the number 
of POM/OTC clients they were treating, only 25% provided a 
dedicated POM/OTC medicines services. All but one, a GP-based 
service, identified themselves as specialist drug treatment services 
and the services reported that treatment was delivered directly 
from the specialist treatment services, GP services (17%) and as 
part of the mental health trust provision (29%) 
All services reported providing structured psychosocial 
interventions but there were a range of responses to providing 
other treatment interventions as defined by the NDTMS 
business definitions (Hinchcliffe, 2010). A tables highlighting the 
proportion of services providing each treatment intervention is 
provided (fig.19).
Figure 19: drug treatment interventions reported to be provided by the 24 
specialist or dedicated services responding to the provider survey.
While dedicated POM/OTC medicines service providers 
unsurprisingly had a majority of clients reporting POM/OTC 
medicines, all but one of the other drug treatment services 
included within the study reported that less than 10% of their 
overall drug treatment population were in treatment in relation 
to POM/OTC medicines and for most services a significant 
proportion of these clients reported POM/OTC medicines 
alongside other concurrent illegal drug use. 
All services that responded to the waiting times question (21 
of 24), reported waiting times of less than four weeks. The 
majority reported waits of less than two weeks (86%). Of those 
services that reported the length in treatment (19 of 24), time in 
treatment varied and while the majority (68%) reported retention 
of longer than six months, some (four out of the 19 services) 
indicated that the average time in treatment time in treatment 
was three months and under. This information could indicate 
that rapid detoxification programmes may have been initiated 
with some POM/OTC medicines clients. To review this, self-
reported information, analysis of the relevant NDTMS data at was 
undertaken where this was available at service level.
Corroborating NDTMS data was available for POM/OTC clients 
Treatment	  intervention	  
Percentage	  of	  services	  reporting	  
providing	  the	  intervention	  
Structured	  psychosocial	  intervention	   100%	  
Advice	  and	  support	   88%	  
Other	  structured	  drug	  treatment	   63%	  
Community	  prescribing	   58%	  
Specialist	  prescribing	   54%	  
GP	  prescribing	   38%	  
Structured	  day	  programmes	   25%	  
Inpatient	  treatment	   13%	  
Inpatient	  treatment	  detoxification	   13%	  
Inpatient	  treatment	  assessment	  only	   9%	  	  
Inpatient	  treatment	  stabilisation	   9%	  	  
Residential	  rehabilitation	   4%	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citing no illegal drug use in 2009-10 for 20 of the 24 services13 
who responded to the questionnaire. Of these, 18 had an average 
waiting time for POM/OTC clients in 2009-10 of under three 
weeks, with ten having an average waiting time of less than a 
week. Eighteen of the 20 services retained clients in treatment for 
longer than three months on average, while 13 retained clients 
for longer than six months on average. Sixteen of the services 
discharged at least half their clients successfully (including onward 
referrals to other agencies); seven of these who discharged all 
clients successfully. However, the numbers of POM/OTC clients 
at many of the services were low and this can have significant 
effects on these indicators.
Services were also asked to call on their experience of working 
with the POM/OTC medicines treatment cohort to identify the 
main ways that people obtain the medicines with which they 
develop problems. All services indicated that prescriptions from 
GPs were a source for many clients, followed by illicit dealers 
and then the internet. Some services indicated that clients also 
obtained these medicines from friends and family while less 
indicated that over the counter purchases and prescription from 
specialist services or hospitals were a potential source of the 
distribution of these medicines.
When asked what the main motivating factors that brought clients 
into drug treatment, most services indicated that this was due to 
the client experiencing negative effects related to dependency or 
from GPs referring them into treatment services after experiencing 
problems reducing or stopping these medicines.
Findings from site visits
Structured discussions were conducted with two to three key 
members of staff from each service. The interview schedule was 
developed to determine what is being provided and how local 
services are configured. It focused on the following key areas
 • Overview of service provision
 • Entering treatment
 • Impact of treatment 
 • Sustainability and future developments
Overview of service provision: all services were found to be 
commissioned by their local partnership area and funded from 
either PCT or LA budgets. The majority of funding for these 
services was established from the pooled treatment budget for 
substance misuse. 
Most services reported working with other providers in order to 
meet the needs of their clients. In the case of GPs, shared care 
and GP referrals were commonly reported as mechanisms of 
joint working. Joint working arrangements with mental health 
services and other drug treatment services were also mentioned.  
More often than not, the service formed part of a multi-agency 
service. Several services reported developing integrated treatment 
pathways, close joint working and in some cases advocacy for their 
clients with other services, such as GP or specialist prescribing.
Relationships between specialist or dedicated treatment providers 
and psychological services or health and social care services 
were reported to be in place but requiring further development. 
Most providers recognised the potential of increasing access to 
psychological therapies (IAPT) programmes to support provision 
for individuals developing problems with POM/OTC medication. 
However, they indicated that links to IAPT programmes were at 
very early stages if there at all.  
Formalised joint working protocols between POM/OTC medicines 
services and other drug treatment providers were reported to 
be in place across most services.  In other services, joint working 
was just based on the understanding and relationships that had 
developed between individual services. The majority of services 
reported to be part of the local areas provider forum which was 
felt to be useful to underpin integrated service provision for 
people experiencing problems with POM/OTC medication. Only 
one service had developed an explicit working relationship with 
pain services.
Entering treatment: it is important to gain an understanding 
of the needs of clients who present with problems in relation 
to prescription only or over the counter medicines. The survey 
revealed three types of clients which access these services, similar 
to the dose dependence grouping described within the Ashton 
Manual (Professor C Heather Ashton DM, 2002):
• therapeutic dose dependence: People who have developed  
 dependence on therapeutic doses of a prescribed or directed  
 medicine
• high dose dependence: people who may have started being  
 prescribed therapeutic dose but escalate their dose, often via  
 illicit sources, but who don’t have other concurrent drug  
 problems
• recreational high dose abuse and dependence: people who  
 have POM/OTC and concurrent illegal drug or alcohol problems.
The main reported problems with POM/OTC medicines, that 
clients presented with were benzodiazepines (e.g. diazepam) 
and Codeine. Other POM/OTC medicines that were mentioned 
included, z-drugs, Tramadol, and brand named codeine containing 
preparations, in both liquid and tablet form.  In the majority of 
cases, clients were thought to have sourced these medicines from 
their GP, pharmacist or over the internet. Other sources included 
‘diverted scripts’ (i.e. those received from patients who have 
elected to sell on their medication) and illicit drug dealers.
Services reported that clients who presented to drug treatment 
were across a range of ages, gender and backgrounds. One 
service suggested that people who report problems in relation to 
codeine tended to be older and were often initially prescribed the 
drug for chronic pain relief. Another service identified a cohort 
of middle aged clients who had been using over-prescribed 
benzodiazepines. Other services identified a cohort of young 
males using illicitly sourced benzodiazepines, while another 
identified problematic use of OTC codeine medicines and alcohol 
by young people in their area. 
13 One service reported late for analysis, and three did not have any reported clients in 2009-10
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The main referral pathways into drug treatment for those who 
had developed problems in relation to the prescribed or directed 
use of medicines were mainly from GP referral and self referral. A 
commonly cited motivator for the former was “the GP identifies 
he/she is prescribing too much and refers the client”. Illicit 
users were reported to be more likely to self refer, motivated by 
wanting to move away from illicit use to licit prescriptions from a 
GP – sometimes because they had lost their ‘enabler’ or dealer. 
Although a large number of self referral cases were recorded, 
services admitted that they did not know how many of their clients 
had seen a GP or health service professional first and then self 
referred as opposed to having been directly referred by a service.
There was general agreement among services that POM/OTC-only 
clients would not and probably should not be treated differently 
from those with other concurrent drug use. They were generally 
reported to be offered the same services as other clients. However, 
the importance of providing services that were sensitive to 
individual needs was recognised, and in areas without dedicated 
services a model of supported GP provision was often favoured. 
One of the dedicated services stated that treating POM/OTC-only 
clients with clients with concurrent illegal drug problems was not 
an issue. The service reported that group work often included a 
mix of both sets of clients and that once they sat down in a room 
together they realised there were little differences in the problems 
people can experience in relation to POM/OTC medicines. 
Impact of treatment: a number of questions were asked to 
gain insight into the interventions and the expected outcomes for 
clients who present with problems in relation to prescription only 
or over the counter medicines.  
Most services reported that the ultimate goal for treatment was 
the abstinence and recovery from all drugs of dependency. In 
terms of POM/OTC provision the most common path was from 
stabilisation to reduction and then abstinence. Few services 
reported a focus on maintenance.
Most services reported having a range of protocols guidance or 
agreements in place to manage the care of individuals developing 
problems in relation to POM/OTC medication. However not all 
services reported having formalised protocols and agreements 
in place covering the full gamut of governance for POM/OTC 
medicine management. Some services reported that further 
national guidance on how to manage issues in relation to POM/
OTC medication would be useful to ensuring improvement and 
the future sustainability of this provision.
Some services reported that they often did not have robust data 
indicating whether or not clients achieved their treatment goals.  
Some services could only report that, ‘most’ clients or ‘all of them’ 
had achieved their goal. One of the dedicated services reported 
that they had good rates of completion, but went on to say that 
“details in relation to the percentage of clients that achieved 
outcomes were difficult to quantify”.
There was a general consensus that treatment of this client 
group was based on individual need and there was a general 
feeling that no differential treatment was needed for POM/
OTC-only and clients with concurrent illegal drug problems. One 
service explained, “If it was felt a client needed extra help with 
other problems they would be referred into specific services e.g. 
substance misuse. If they felt they had problems with alcohol they 
would be co-worked. It was the same for mental health.” 
Services agreed there were other outcomes that could be 
delivered as part of their treatment provision, particularly 
in relation to reintegration and recovery. Services reported 
supporting clients into volunteering, training, employment and 
housing. However it was felt that further integration between 
their service and initiatives such as the Department for Work and 
Pension (DWP) Progress to Work scheme could further enhance 
service provision and outcomes in relation to getting people back 
to work.
Sustainability and the future: services were asked a number 
of questions to gain an understanding of the sustainability of 
treatment provision, potential changes in demand and ability to 
meet demand in the future.  
Three services had concrete ideas or plans for the future of their 
service. One service explained that they would be integrating with 
the alcohol service and will then look at how to ‘skill up’ staff. 
They were also exploring the possibility of applying to become 
one of the pilot services for payment by results. One service 
identified that there was a significant unmet need and explained 
that as a result, capacity would become an issue. Another service 
mentioned they would like to increase accessibility e.g. out of 
hours opening was needed as most of these clients work so they 
would aim to expand service hours.
Half of the services (three) confirmed that they had been 
consulted or involved in their partnership area Joint Strategic 
Needs Assessment.
A lack of future plans may be associated with a lack of 
monitoring. Some of the services indicated that there was a 
need to improve data quality and performance monitoring in 
order to drive service improvement and continue to meet any 
changes in trends in the problems associated with POM/OTC 
medication. Two of the services reported an increasing trend in 
the number of those accessing services in relation to internet 
sourced benzodiazepines; another reported an increasing number 
of young people being referred for problems in relation to the use 
of benzodiazepines that included violent behaviour.
The providers were asked what they felt needed to be addressed 
nationally in relation to the problems that can develop from the 
use of POM/OTC medication. While some services recognised 
that there had been an improvement in relation to the prescribing 
of these medicines, particularly benzodiazepines, some felt that 
further improvements were necessary particularly in relation to the 
25
NTA 2011
management of repeat prescriptions. The services also reported 
that more access into psychological therapies as alternatives or  
complimentary to prescribed medication was needed as well as 
improved national guidance or examples of best practice on how 
to treat problems in relation to POM/OTC. Finally, some services 
also reported that a public health campaign or event would be 
useful for raising awareness at a national level. 
Discussion
All services recruited to this study were able to report data to 
the national drug treatment monitoring system (NDTMS). While 
some services might need further clarity about the reporting 
requirements in relation to POM/OTC medicines, this does mean 
that the treatment service’s provision for those who encounter 
problems with POM/OTC medicines can be monitored at a 
national level. Reports from the site visits suggest that some local 
services would benefit from enhancing their local performance 
management systems to better understand how they are meeting 
the needs of this client group. 
Specialist and dedicated services were provided from the 
community and voluntary sector and funded from local PCT 
and LA budgets. The majority of funding for these services was 
reported to come from the Pooled Treatment Budget.
 Specialist drug treatment services indicated that while the 
majority of POM/OTC clients have concurrent problems with other 
illegal drugs, a small proportion of their clients do report problems 
with POM/OTC alone. As would be expected, dedicated services 
reported a much higher proportion of POM/OTC-only clients, but 
these services also reported meeting the needs of those who also 
had problems in relation to illegal drugs.  
The site visits confirmed that treatment was provided in order to 
meet individual need and in that sense there was no difference 
in terms of access or treatment provided between POM/OTC-
only and POM/OTC+ illegal drug using clients. However it was 
understood that traditional drug treatment services were not 
always appropriate for POM/OTC-only clients and where dedicated 
services were not in place, a model of supported GP provision was 
preferred. However, dedicated POM/OTC services could be run 
from GP practices and generic drug treatment services.
Services were reported to be provided across a variety of settings 
including wider mental health and GP shared care. All services 
reported providing talking therapies (structured psychosocial 
intervention) and most indicated access to a range of prescribing 
support. Fewer services indicated they could provide direct access 
to inpatient treatment, detoxification, stabilisation or residential 
rehabilitation. This is not unexpected as drug treatment services, 
particularly the smaller dedicated services, are likely to refer into 
these more intensive treatments rather than provide them directly.  
Information from the site visits supported the information gathered 
by the survey and indicated that most specialist and dedicated 
services had local agreements for the referral of POM/OTC clients 
into more intensive treatment interventions such as detoxification 
and rehabilitation where this was assessed as a clinical need.
Performance data from this sample of services indicates that 
the majority had waiting times within the national performance 
expectations for wider drug treatment services (less than three 
weeks). Waiting times are commonly used in health performance 
statistics as a measure of how well services are meeting demand.  
This information from dedicated and specialist services might 
suggest that services are meeting the local demand in relation to 
POM/OTC. This assumption does not take into account questions 
of the accessibility of drug treatment services to particularly, POM/
OTC-only users. However, the length of time in treatment and 
higher proportions of planned exits reported for the POM/OTC-
only cohort does indicate that these services are meeting the 
individual needs of this cohort.
The providers targeted as part of the site visits identified a range 
of national support that they felt would support them to address 
the issues of POM/OTC medicines. These included: tighter 
monitoring and regulation of repeat prescriptions; more access 
into psychological therapies as alternatives or as a compliment 
to prescribed medication; national guidance or examples of 
best practice on how to treat problems in relation to POM/
OTC medicines and also national public health campaigns to 
raise awareness of the issues in relation to these medicines and 
reducing the stigma of mental health problems. 
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conclusion
The directed uses of all of the medicines considered within 
this report are supported by a wealth of scientific and medical 
evidence. There is no doubt that for many people they bring 
significant comfort from a range of distressing and debilitating 
diseases. Unfortunately, some people do experience negative 
side effects, that override the desired effects of these drugs 
and a number can experience problems when discontinuing 
their medication. In addition these medicines carry with them a 
potential for misuse.
England has developed an accessible drug treatment system by 
enabling local areas to commission drug treatment services that 
reflect and meet local need. The drug treatment system has been 
predominantly focused on the treatment of heroin and crack 
cocaine. This has led to some suggesting that drug treatment 
services are neither available nor accessible to those who develop 
problems in relation to POM/OTC medicines.
Using national prescription and drug treatment data, and in 
extensive consultation with the field, this study attempted to 
determine the likely prevalence of treatment need in relation to 
POM/OTC and the current availability of services to meet that 
demand. 
The study found that there has been a significant increase in the 
prescribing of opioid analgesics over the last 19 years, while the 
overall quantity of benzodiazepine medication has fallen steady 
over the same period. This indication that benzodiazepines 
are being prescribed in reduced doses is supported by findings 
from consultation with local partnerships reporting an increased 
vigilance over the prescribing of these medicines. The reports of 
an increased vigilance of prescribing may be reflected in national 
drug treatment data indicating that the number of people coming 
into drug treatment reporting problems with benzodiazepines 
(without concurrent drug problems) has fallen consistently over 
the past five years.
The increase in the prescribing of opioids does not seem to 
be reflected in an increase in the numbers presenting for drug 
treatment, evidenced by national drug treatment data, but the 
data do report an increase within the POM/OTC-only cohort, of 
individuals reporting problems with other prescribed drugs14 and 
over the counter opioids. 
 
Importantly, the national drug treatment data does evidence that 
some people who only report problems in relation to POM/OTC 
do have access to drug treatment and once they are in treatment 
they engage well and achieve comparatively better outcomes than 
the illegal drug-using treatment population. 
Although the trends in prescribing and access into drug 
treatment services are useful in determining areas where there 
might be a higher prevalence of issues in relation to POM/
OTC, the data available at national level tells us little about the 
prevalence of addiction or substance dependence disorders. 
National prescription data does not collect information about 
the length of prescription and systems to collect information 
on repeat prescription are not yet fully embedded, preventing 
the identification of long-term prescribing of these medicines.  
Looking at all individuals in treatment during 2009-10, of the total 
number 32,510 people reporting problems in relation to POM/
OTC, only 3,735 report this without reference to other problem 
drug use. So while some POM/OTC-only clients access and do well 
in drug treatment there might well be another other population 
of individuals who wouldn’t dream of stepping foot inside a 
traditional drug treatment service.
From the consultation with local partnerships, specialist drug 
treatment and dedicated POM/OTC service providers it was clear 
that the issue of unmet need was something they struggled with. 
Local prescribing data do provide further granularity enabling 
the identification of prescribing practices and even patients that 
might require targeted support. However local monitoring and 
information systems in relation to POM/OTC were felt to need 
further development. One area identified important improvements 
needed to the software systems that captured prescribing data 
and suggested that this could be addressed by updating the 
minimum standard requirements for software suppliers set 
nationally by Connecting for Health15. 
While most partnerships who responded to this study reported 
that they had some local knowledge in relation to POM/OTC 
medicines it was clear that there was a range of understanding 
regarding the extent of the local problem. Some relied solely on 
drug treatment data as an indication of demand, while other 
areas worked with GPs, mental health services, pharmacies, 
the police and a range of other partners to develop a detailed 
local picture of demand in relation to prescription only and over 
the counter medicines that fed into their Joint Strategic Needs 
Assessment.
Local partnerships and services recognised the importance of 
personalised services and were reported to be addressing the 
issue by commissioning and providing services based on individual 
need. Partnerships and services highlighted the importance of a 
flexibility of approach and therapeutic alliance with their clients 
in order to engage people who develop problems with POM/
OTC medicines. Where they existed, dedicated POM/OTC services 
were described as a valued aspect of the drug treatment system; 
other areas stated that a model of supported GP provision was 
a preferred choice for POM/OTC clients. This suggests that some 
individuals seeking support in relation to POM/OTC could be 
provided services such as mental health and primary care provision 
that currently fall outside of reporting to NDTMS and hence little 
data exists on the treatment of these individuals, or the availability 
of this type of treatment provision.
Many of those consulted highlighted the importance of joined-
up services and already had in place a range of agreements with 
other partners such as GPs, mental health services, and other 
drug treatment providers. Areas for further development that 
14 Usually reported as ‘prescription drug – not defined’ within the national dataset
15 Connecting for Health is part of the Department of Health Informatics Directorate, whose role is to maintain and develop the NHS national IT infrastructure
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were highlighted were pain services, reflecting a perception of a 
potential future trend towards pain medication  and increasing 
access to psychological therapies  IAPT provision, which was seen 
as a potential resource for preventive activity and as a potential 
complement to reduction regimes.
Partnerships expressed concerns about how a potential increase 
in demand could be met within current resources and both 
partnerships and services indicated that there was still some 
confusion over the way in which services in relation to POM/OTC 
should be delivered. Clear national guidance on the responsibility, 
commissioning and best practice provision of these services was 
requested and felt to be particularly important in light of future 
commissioning arrangements.
The problems that some people can develop from the prescribed 
and directed use of these medicines can have a significant and 
devastating impact on their lives and it is clear that the illicit use of 
these drugs can severely hamper someone’s recovery from other 
drugs of dependency. It is clear that irrespective of the source of 
these drugs, or the reasons for taking them, all people in need of 
treatment should be able to access the support they need. The 
national drug strategy, 2010 (HM Government, 2010) broadens 
the focus of drug treatment to consider dependence on all 
drugs. There is a responsibility to continue to develop services to 
ensure that all people, including those who develop addiction or 
substance dependence problems with prescription only and over 
the counter medicines, can achieve recovery and ultimately the 
best possible chance to lead a drug-free life.
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glossary
ADQ: average daily quantity
Analgesics: drugs to relieve pain
Anxiolytics: a class of drug used in the treatment of anxiety
Barbiturates: a class of drugs that act as central nervous system 
depressants, and, by virtue of this, they produce a wide spectrum 
of effects, from mild sedation to total anaesthesia
Benzodiazepine: a class of drugs that have sedative, sleep-
inducing, anti-anxiety, anticonvulsant, muscle relaxant and 
amnesic action.
BNF: British National Formulary
BPS: British Pain Society
CSM: Committee on Safety of Medicines
DAT: Drug and Alcohol Team (the local strategic partnership 
responsible for addressing local issues in relation to drug and 
alcohol problems)
Directed use: the use of POM/OTC medicines in the way they 
have been prescribed by a qualified medical professional
Effective treatment: clients defined as being engaged in 
effective treatment are all those clients who are retained in 
treatment for more than 12 weeks, or if exiting treatment before 
12 weeks, were free of dependency at exit
e.PACT: Electronic Prescribing Analyses and Costs (data)
Exiting treatment, completing successfully: clients defined as 
being discharged from treatment, completing treatment free of 
their drug of dependency
GP: General Practitioner
Hypnotics: a class of drugs whose primary function is to induce 
sleep
IAPT: Increasing Access to Psychological Therapies
Modality/intervention: a type of treatment, e.g. structured 
counselling, specialist prescribing etc.
NAC: National Addiction Centre
NATMS: National Alcohol Treatment Monitoring System
NDTMS: National Drug Treatment Monitoring System
NIC: Net Ingredient Cost
NICE: National Institute for Clinical Excellence
Non-directed use: the use of medicines by an individual for 
whom they have not be prescribed or taking doses of a medicines 
above prescribed levels
NTA: National Treatment Agency for Substance Misuse
Opioid: a classification of drugs with opium or morphine-like 
pharmacological action
OTC: over-the-counter medicine
Partnerships: the local strategy partnership responsible for 
delivering the drug strategy at a local level (often known as the 
Drug and Alcohol Action Teams or DAAT)
PCT: Primary Care Trust – a type of NHS trust that exists in every 
local area responsible for the commissioning and delivery of 
primary and community health services
POM: prescription-only medicine
PPA: Prescription Prescribing Authority
Psychotropic: a drug that acts primarily on the central nervous 
system where it affects brain function, resulting in changes in 
mood, perception, consciousness, cognition and behaviour
RCGP: Royal College of General Practitioners
SHA: Strategic Health Authorities
STAR-PU: Specific Therapeutic Age-Sex Related Prescribing Unit
Structured drug treatment: Structured drug treatment follows 
assessment and is delivered according to care plans, which are 
regularly reviewed with the client. It may comprise a number of 
concurrent or sequential treatment interventions
Waiting times: the period from the data a person is referred for a 
specific treatment modality and the date they start that modality.
z-drugs: a group of non benzodiazepine drugs with effects similar 
to benzodiazepines which are used in the treatment of insomnia
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annEx 1
Medicines reported in the NDTMS core data set and the categorisation into prescribed and over the counter medicine groups identified as 
being of interest to the addiction to medicines steering group.
Prescription-only (POM) or  
over-the-counter (OTC) medicine
Secondary classification Substance name as it appeared  
in the NDTMS data set
POM Prescribed opioids Opioids unspecified
Morphine sulphate
Dihydrocodeine
Dextromoramide
Dipipanone
Pethidine
Morphine sulphate amps
Hydromorphine
Oxymorphone
Hydrocodone
Oxycodone
Levorphanol
Phenazocine
Piritramide
Pentazocine
Dextropropoxyphene
Nalbuphine
Alphaprodine
Anileridine
Ethoheptazine
Fentanyl
Phenoperidine
Meptazinol
Papaveretum
Tramadol hydrochloride
Other opioids
POM Analgesics Opioid compound analgesics
POM Benzos Benzodiazepines unspecified
Diazepam
Chlordiazepoxide
Nitrazepam
Lorazepam
Clobazam
Clorazepate
Ketazolam
Medazepam
Oxazepam
Flurazepam
Temazepam
Triazolam
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Prescription-only (POM) or  
over-the-counter (OTC) medicine
Secondary classification Substance name as it appeared  
in the NDTMS data set
POM Prescribed opioids Lormetazepam
Prazepam
Bromazepam
Flunitrazepam
Chlormezanone
Loprazolam
Alprazolam
Clonazepam
Midazolam
POM z-drugs16 Zoplicline
Zolpidem tartrate
POM Barbiturates Barbiturates unspecified
Amylobarbitone
Pentabarbitone
Quinalbarbitone
Phenobarbitone
Butobarbitone
Heptabarbitone
Cyclobarbitone
Hexobarbitone
Barbitone unspecified
Methylphenobarbitone
POM Prescription Diamorphine prescription
Codeine prescription
Other prescribed drugs
OTC OTC opioids Codeine tablets17
Codeine unspecified
Opioid containing mixture
Codeine linctus
Gee's Linctus
Collis-brown
Phensedyl
Actifed
Kaolin & morphine
OTC Antihistamines Antihistamine unspecified
Hydroxyzine
Cyclizine
Promethazine
16 Zaleplon is not included within the current NDTMS drug list and hence is not reported here
15 Note this is not specifically identified as a single ingredient compound within the NDTMS dataset hence it has been included as an OTC within the analysis. Some reporting 
of codeine tablets could be single ingredient and might over inflate the numbers reported within the OTC category
31
NTA 2011
annEx 2
Addiction to Medicine specification – overview of project 
deliverables
There are three elements to the report into addiction to medicine 
commissioned by the Department of Health from the NTA. These 
include;
 • an analysis of relevant NDTMS and other data
 • structured interviews with targeted PCTs
 • surveys and structured interviews with dedicated and specialist  
 providers
Results from above elements will be complied into a single review 
report to provide an overview of the level and configuration of 
current service provision to support those who develop problems 
with prescribed or over the counter medicines.
The scope of this project will include consideration of; use 
within illegal drug using treatment population, relationship with 
addiction and pain services, psychotropic’s and opioid medication.
1. Data analysis
Product description: a written report on the findings of 
analysis of NDTMS and Pharmacy data in relation to addiction to 
medicines.
Aims 
Using national NDTMS and pharmacy data to identify:
 • the level and spread of service provision for those presenting  
 with problems in relation to prescribed and over the counter  
 medicines
 • how services perform in relation to this cohort, compared to  
 national data on services for “illegal” drug users.
 • the demographics of this in-treatment cohort 
 • any trends in presentation to services over the past five years
 • high yield PCT’s and services that could be the focus of further  
 investigation.
Method
Identify and agree the cohorts for investigation. Using NDTMS 
and NATMS data run analysis against new treatment journeys and 
in year stock data to identify an addiction to medicine cohort by 
excluding those with reference to PDU, or powder cocaine use 
across their entire treatment journey. 
Develop presentation for cross departmental groups and write up 
analysis as part of wider report document
2. PCT Questionnaire/interview (eight targeted partnerships)
Product description: a written report on the findings from 
structured interviews with PCTs in relation to the commissioning, 
governance and provision of services to support those that develop 
problems in relation to prescribed and over the counter drugs.
Aims
 • determine the local practice and governance re: repeat   
 prescriptions for benzodiazepines
 • determine understanding of preventative measures in   
 relation to addiction to medicines 
 • determine understanding of the how local services are   
 configured and commissioned to support those who might  
 develop problems in relation to these medicines
 • understand the presenting needs characteristics of this   
 population and how services are configured to meet need
 • understand the outcome of any recent auditing of   
 benzodiazepine and z-drug provision
 • highlight any best practice for wider implementation
 • determine what could be done to support service   
 improvements.
Method
Target PCT’s to be identified as those that; commission dedicated 
services, have undertaken a prescribing audit or who are identified 
as having high levels of repeat prescription for said drugs and/
or are identified through NDTMS data as having a high yield of 
clients presenting to drug treatment services stating said drugs as  
being problematic.
Target PCT’s to be approached and asked if they are willing 
to engage in the project. Those accepting involvement will be 
interviewed as part of a focus group to include; the drug and 
alcohol commissioner, pharmacy lead, provider representative and 
any other relevant representatives that are defined locally.
An analysis of the local NDTMS and pharmacy data will be 
shared with the local PCT and used alongside the local audit 
data (if available) as a focus for the interview. The NTA will lead 
discussions using a structured interview schedule (common to all 
interviews).
Interviews will be written up and the findings bought together 
and published as part of the final report.
nb. Where face to face interviews are not possible, conference 
calls may be considered as an alternative
3. Provider survey (10-15 providers)
Product description: A written report highlighting the results 
of  a provider survey and qualitative interviews to determine how 
local services are configured and commissioned to support those 
who develop problems in relation to prescribed and over the 
counter drugs. 
Aim
 • determine understanding of the how local services are   
 configured and commissioned to support those who might  
 develop problems in relation to these medicines
 • determine;
 • what interventions are offered
 • what is the capacity and through-put    
 • performance: waiting times, engagement, planned exits
 • relationship and pathways with other services, Pain, GP,  
 Additions and mental health services – link in IADPT access
 • client demographics
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 • whether there is a distinction between services for those  
 who develop problems in relation to the directed use of  
 these medicines and those who develop problems in relation  
 to the non-directed use of these medicines, including clients  
 with problems in relation to other concurrent illegal drug use.
Method
Use NDTMS analysis to identify services with a high yield of clients 
reporting problems with prescription or over the counter drugs. 
These services and those identified as providing a dedicated 
prescription or over the counter treatment service are to be 
approached to request their involvement in the study
Those services that agree will be asked to complete a provider 
survey to establish some local data on the provision and capacity 
of current services and this will be followed up with site visits to 
some providers to undertake a structured interview to provide 
further detail on the presenting needs of their clients and the 
provision and configuration of local services.
Interviews will be written up and the findings bought together 
and published as part of the final report.
nb: Where face to face interviews are not possible, conference 
calls may be considered as an alternative
